Jmjd2c/Kdm4c facilitates the assembly of essential enhancer-protein complexes at the onset of embryonic stem cell differentiation

Rute A. Tomaz¹, Jennifer L. Harman², Donja Karimlou¹, Lauren Weavers¹, Lauriane Fritsch³, Tony Bou-Kheir¹, Emma Bell¹, Ignacio del Valle Torres⁴, Kathy K. Niakan⁴, Cynthia Fisher⁵, Onkar Joshi⁶, Hendrik G. Stunnenberg⁶, Edward Curry¹, Slimane Ait-Si-Ali³, Helle F. Jørgensen² and Véronique Azuara¹*

1- Institute of Reproductive and Developmental Biology, Faculty of Medicine, Imperial College London, London W12 0NN, UK.
2- Cardiovascular Medicine Division, Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.
3- Centre National de la Recherche Scientifique CNRS - Université Paris Diderot, Sorbonne Paris Cité, Epigenetics and Cell Fate, UMR 7216 CNRS, Paris, France.
4- Mill Hill Laboratory, The Francis Crick Institute, London NW7 1AA, UK.
5- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1HH, UK.
6- Radboud University, Faculty of Science, Department of Molecular Biology, 6525GA Nijmegen, the Netherlands.

*Corresponding author. Véronique Azuara, Epigenetics and Development Group, Institute of Reproductive and Developmental Biology, Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK. E-mail: v.azuara@imperial.ac.uk

Keywords: Jmjd2c/Kdm4c, enhancers, gene regulation, embryonic stem cells, epiblast stem cells, lineage specification.
Abstract

Jmjd2/Kdm4 H3K9-demethylases cooperate in promoting mouse embryonic stem cell (ESC) identity. However, little is known about their importance at the exit of ESC pluripotency. Here, we uncover that Jmjd2c facilitates this process by stabilizing the assembly of Mediator-Cohesin complexes at lineage-specific enhancers. Functionally, we show that Jmjd2c is required in ESCs to initiate appropriate gene expression programs upon somatic multi-lineage differentiation. In the absence of Jmjd2c, differentiation is stalled at an early post-implantation epiblast-like stage, while Jmjd2c-knockout ESCs remain capable of forming extra-embryonic endoderm derivatives. Dissection of the underlying molecular basis revealed that Jmjd2c is re-distributed to lineage-specific enhancers during ESC priming for differentiation. Interestingly, Jmjd2c-bound enhancers are co-occupied by the H3K9-methyltransferase G9a/Ehmt2, independently of its H3K9-modifying activity. Loss of Jmjd2c abrogates G9a recruitment and furthermore destabilizes loading of the Mediator and Cohesin components Med1 and Smc1a at newly activated and poised enhancers in ESC-derived epiblast-like cells. These findings unveil Jmjd2c-G9a as novel enhancer-associated factors, and implicate Jmjd2c as a molecular scaffold for the assembly of essential enhancer-protein complexes with impact on timely gene activation.
Introduction

Pluripotency, the ability of a cell to generate all somatic lineages, is transiently acquired in vivo during mammalian pre-implantation development. Upon blastocyst formation, pluripotent cells develop within the inner cell mass (ICM), a mosaic of cells surrounded by an extra-embryonic layer - the trophectoderm. By the time of implantation, a second extra-embryonic lineage, the primitive endoderm, emerges at the ICM surface. Concurrently, the ICM maintains its pluripotency as it matures into the epiblast but ultimately goes on to form the three primary germ layers and germ cells upon gastrulation (Boroviak and Nichols, 2014; Rossant, 2008).

Pluripotent mouse embryonic stem cells (ESCs) are derived from ICM cells, and can self-renew and faithfully maintain an undifferentiated state in vitro in the presence of leukaemia inhibitory factor (LIF) and serum components while preserving their multi-lineage differentiation capacity (Evans and Kaufman, 1981; Martin, 1981; Niwa et al., 1998; Ying et al., 2003). Most recently, stem cell lines with similar lineage potential were established from other developmental stages (Chung et al., 2006; Tesar, 2005), including a number of post-implantation epiblast-derived stem cells (EpiSCs) (Brons et al., 2007; Osorno et al., 2012; Tesar et al., 2007). While ESCs are thought to represent an immature (pre-implantation) phase of pluripotency, EpiSCs exist in a more advanced state on the verge of differentiation (Nichols and Smith, 2009). Moreover, ESCs can stably transit into self-renewing EpiSCs, acquiring characteristics of post-implantation epiblast-like cells (Guo et al., 2009).

ESC abilities depend on the potent expression of self-renewal genes and transcriptional priming of silent, lineage-affiliated genes – a critical balance of gene expression maintained through crosstalk between transcriptional factors and chromatin regulators (Azuara et al., 2006; Bernstein et al., 2006; Chen and Dent, 2014; Ng and Surani, 2011; Stock et al., 2007). Remarkably, both active (ESC-specific) and primed (lineage-specific) genes are expressed in a heterogeneous manner, a feature long considered a hallmark of ESC cultures to safeguard the swift response to differentiation cues (Efroni et al., 2008; Torres-Padilla and Chambers, 2014). Yet, it is now possible to derive and maintain ESCs with reduced
heterogeneity and transcriptional gene priming through chemical inhibition of two differentiation-associated pathways Mek and Gsk3 (2i conditions), capturing a naïve pluripotent state in vitro (Marks et al., 2012; Ying et al., 2008).

Gene promoter regions enriched in CpG islands and H3K4me3 function as genomic platforms for the recruitment of transcription factors and co-regulators as well as the basal transcriptional machinery (Deaton and Bird, 2011; Illingworth and Bird, 2009). Moreover, distal DNA elements such as enhancers play a significant role in potentiating gene expression being typically decorated by H3K4me1 and bound by pioneer transcription factors (Calo and Wysocka, 2013; Gibcus and Dekker, 2013; Spitz and Furlong, 2012). For example, the core pluripotency factor Oct4 was commonly shown to mark both active and poised enhancers in ESCs and EpiSCs (Buecker et al., 2014; Calo and Wysocka, 2013). Enhancer activity and robust ESC-specific gene expression entail long-range DNA interactions with the transcriptional apparatus at promoters, involving the cooperative action of Mediator-Cohesin complexes (Kagey et al., 2010). Yet, relatively little is known about the identity of proteins that stabilize the formation of such assemblies.

Histone demethylases have emerged as key players in the control of cell identity and development mainly through modulation of the chromatin environment of tissue-specific genes (Nottke et al., 2009). Recently, additional roles for these molecules independent of their enzymatic activity were reported (Shpargel et al., 2012; Wang et al., 2012; Yang et al., 2010), especially in regulating the recruitment of Polycomb repressive complexes (PRC) and poised RNA polymerase II to the promoter regions of developmental genes in ESCs (Farcas et al., 2012; Wu et al., 2013). Jmjd2c/Kdm4c is a member of the Jmjd2/Kdm4 gene family initially identified as H3K9me2/3 and/or H3K36me2/3 histone demethylases (Chen et al., 2006; Klose et al., 2006; Whetstine et al., 2006). Jmjd2c is highly expressed in the early embryo and in ESCs (Boroviak et al., 2015; Burton et al., 2013; Loh et al., 2007; Wang et al., 2010), and RNA interference-mediated depletion of the protein was shown to impair cleavage-stage development and ESC integrity as well as inhibiting somatic cell reprogramming (Das et al., 2014; Loh et al.,
Jmjd2c-null ESCs and mice could, however, be generated via gene trap approaches (Pedersen et al., 2014), in agreement with functional redundancy between Jmjd2 gene family members to support cell proliferation and survival (Pedersen et al., 2016). At the genomic level, Jmjd2c was shown to preferentially target H3K4me3-rich promoter regions of active and developmental-associated genes in ESCs via its Tudor domains (Das et al., 2014; Pedersen et al., 2014), where Jmjd2c was proposed to assist Jmjd2b-Nanog and PRC2 in transcriptional activation and repression, respectively (Das et al., 2014).

In this study, we uncover a previously unrecognized link between Jmjd2c recruitment to lineage-specific enhancers and the establishment of a functionally primed state for differentiation in vitro. We show that, in the absence of Jmjd2c, ESC differentiation is severely impeded at an early post-implantation epiblast-like stage. While Jmjd2c-knockout ESCs can transit into self-renewing EpiSCs, these cells fail to form derivatives of the three primary germ layers, as revealed by their inability to initiate appropriate gene expression programs. In contrast, Jmjd2c-knockout cells remain capable of adopting extra-embryonic endoderm-like phenotypes under permissive conditions. Mechanistically, we show that Jmjd2c is re-distributed to lineage-specific enhancers in primed (serum/LIF) as opposed to naïve (2i/LIF) ESCs. Strikingly, Jmjd2c-bound enhancers are co-occupied by the antagonistic enzyme G9a/Ehmt2, independently of its silencing H3K9-modifying activity.

We show that Jmjd2c-G9a co-occupancy coincides with the formation of activating, Med1-containing enhancer complexes. Loss of Jmjd2c abrogates G9a recruitment at Jmjd2c-bound distal sites, and this correlates with inefficient loading of Mediator-Cohesin complexes in ESC-derived EpiSCs with impact on gene activation upon lineage specification. Collectively, these data reveal that Jmjd2c is required for successful gene transcription and somatic differentiation in pluripotent stem cells, and propose a novel regulatory role for Jmjd2c in stabilizing the assembly of essential enhancer-protein complexes at the onset of ESC differentiation.
Results

Jmjd2c is required for embryonic stem cell differentiation towards somatic lineages

Combining genetic deletion and functional assays, we tested whether Jmjd2c plays a role at the exit of pluripotency. Jmjd2c mutant and wild-type JM8-ESCs were obtained through the EUCOMM/IKMC repository (Bradley et al., 2012; Skarnes et al., 2011), and targeting of both Jmjd2c alleles in Jmjd2c-knockout (E2 and E3) ESC clones confirmed by long-range PCR and GFP expression (Fig. S1A-C). Western blotting validated that full-length Jmjd2c protein expression was completely abolished in Jmjd2c-knockout samples (Fig. 1A). This was accompanied by a notable increase in bulk H3K9me2 levels relative to wild-type (Fig. 1B, S1D); an effect attributed to Jmjd2c loss itself in the continued expression of other H3K9-demethylases and methyltransferases (Fig. S1D-E). Constitutively Jmjd2c-depleted E2 and E3 ESC clones grew normally in medium supplemented with serum plus LIF (Fig. S1F), in agreement with a similar conditional knockout model (Pedersen et al., 2014). When plated at low density these cells also displayed comparable proportion of undifferentiated colonies relative to their wild-type counterparts (Fig. 1C), despite reduced expression levels of pluripotency-associated factors (Fig. S1G). Jmjd2c depletion did not, however, result in general de-repression of differentiation-associated genes (Fig. S1H), including those co-bound by Jmjd2c and PRC complexes at their promoter regions (Das et al., 2014). These data indicate that constitutive Jmjd2c-knockout ESCs retain a self-renewing and undifferentiated phenotype in pluripotency culture conditions.

To assess the effect of Jmjd2c-deficiency on differentiation, Jmjd2c-knockout and wild-type ESCs were induced to form embryoid bodies (EBs) (Fig. 1D-E). In contrast to the dispensability of Jmjd2c for ESC self-renewal, Jmjd2c-deficient cells were unable to properly differentiate into derivatives of the three germ layers. These cells formed smaller EBs (Fig. 1D), which, in contrast to wild-type EBs, showed residual expression of the pluripotency factors Oct4 and Nanog (Fig. 1E, upper panel). Notably, Jmjd2c-knockout EBs showed impaired expression of the epiblast marker Fgf5 and several mesoderm, endoderm and ectoderm germ layer-affiliated genes (Fig. 1E,
lower panels). Importantly, this defect was recapitulated using another loss-of-function strategy (Fig. S2). Using validated puromycin-selectable shRNA vectors (Loh et al., 2007), we could indeed stably establish several Jmjd2c-knockdown E14-ESC clones (Fig. S2A-C). As Jmjd2c-knockout ESCs, these clones proliferated normally showing no incidence of spontaneous differentiation and/or prominent gene de-repression (Fig. S2D-E). Moreover, we found that Jmjd2c-knockdown ESCs failed to potently activate Brachyury and Mixl1 upon EB formation despite evidence for Fgf5 induction at variable levels in different clones and experiments (Fig. S2F; data not shown). Collectively, these findings demonstrate that Jmjd2c is important for the successful differentiation of ESCs into multiple somatic lineages.

Strikingly, however, Jmjd2c-deficient cells could differentiate upon LIF withdrawal and addition of all-trans retinoic acid (atRA), indicating that not all differentiation pathways in ESCs were compromised in the absence of Jmjd2c. Differentiation was evidenced by a complete loss of Oct4 expression (Fig. 1F), and prominent upregulation of Gata6, Gata4, Sox7, and Dab2 transcripts (Fig. 1G), consistent with the preferential acquisition of a primitive endoderm (PrE)-like phenotype under these conditions (Artus et al., 2010; Capo-Chichi et al., 2005). In atRA-treated wild-type ESCs, PrE-like differentiation was marked by the swift downregulation of Jmjd2c (Fig. 1G, bottom panel), similar to what was observed upon trophoblast lineage commitment in vitro (Alder et al., 2010). These findings corroborate with in vivo studies showing that Jmjd2c expression is dynamically lost in the primitive endoderm while being retained in the epiblast of peri-implantation embryos (Fig. S3) (Boroviak et al., 2015; Burton et al., 2013). Hence, Jmjd2c might be expendable for the formation of extra-embryonic lineages where it is not normally expressed; an observation that was substantiated by the successful generation of extra-embryonic endoderm (XEN) stem cells from Jmjd2c-knockout ESCs (Fig. S4) (Cho et al., 2012; Kunath et al., 2005; Niakan et al., 2013). Collectively, our results support a selective requirement for Jmjd2c during epiblast-derived lineage specification.
**Lack of transcriptional gene priming and skewed cell fate in Jmjd2c-deficient epiblast stem cells**

To explore the timing of Jmjd2c function in somatic differentiation, we first examined whether Jmjd2c was required during the transition from ESC to EpiSC pluripotent states (Guo et al., 2009). Both *Jmjd2c*-knockout and wild-type EpiSC lines could be stably established (Fig. S5). However, during this process, we noticed a delay in the induction of the early EpiSC markers, *Otx2* and *Dnmt3b* (Tesar et al., 2007; Veillard et al., 2014) in *Jmjd2c*-knockout relative to wild-type ESCs when treated with Activin and Fibroblast growth factor (Fig. S5A). Notably, lower *Fgf5* mRNA levels were detected in stably converted EpiSCs (cEpiSCs) in the absence of Jmjd2c. Hence, while *Jmjd2c*-deficient ESCs retain the ability to convert into EpiSCs, these cells harbour an incomplete/immature epiblast-like state, as further suggested by a lack of low-level transcript detection at primed germ layer (*Brachyury* and *Foxa2*) markers in *Jmjd2c*-knockout cEpiSCs (Fig. S5A, lower panel).

To determine whether *Jmjd2c*-deficiency also impacts on the ability of cEpiSCs to respond to differentiation cues, we compared the behaviour of *Jmjd2c*-knockout and wild-type cEpiSCs when prompted to differentiate towards mesodermal lineages. Here, we used a protocol adapted from a human ESC differentiation model (Cheung et al., 2012) to induce early mesodermal (EM) progenitors and mature lateral plate (LPM) and paraxial (PM) mesodermal cell types (Fig. 2A). Both control EpiSCs and wild-type cEpiSCs readily acquired an EM-like identity, as typified by the loss of *Fgf5* expression and acquisition of the early primitive streak marker *Brachyury* at day 1-1.5 post-induction (Fig. 2B). In contrast, we found that *Jmjd2c*-knockout cEpiSCs were unable to efficiently progress into early, *Brachyury*-positive, mesodermal progenitors, confirming that differentiation blockage occurs at an early epiblast-like stage in the absence of Jmjd2c.

All three cell lines were further differentiated under LPM and PM conditions, generating Flk-1 and Pdgfrα expressing cell populations, respectively, as monitored by flow cytometry at day 4 post-induction (Fig. 2C). While the wild-type cEpiSC response closely mirrored that of embryo-derived EpiSCs, differentiation into mature cell types was blocked in *Jmjd2c*-knockout
cultures, showing impaired expression of LPM (*Kdr/Flk-1* and *Isl1*) and PM (*Pdgfra* and *Meox1*) markers. Instead, and irrespective of LPM and PM conditions, *Jmjd2c*-knockout cells induced typical post-implantation extra-embryonic endoderm (*Lrp2* and *Sparc*) but not definitive and pan endodermal (*Cxcr4* and *Foxa2*) markers (Fig. 2D, right panels). Moreover, these cells acquired an adhesive, polarized epithelium-like morphology (Fig. 2E), and stained positive for E-Cadherin (Fig. S6) similar to what is observed upon BMP4-induced differentiation of XEN cells (Artus et al., 2012; Paca et al., 2012). Collectively, our findings suggest that, in the absence of *Jmjd2c*, epiblast cell fate might default towards extra-embryonic endoderm-like derivatives, as tested here upon mesodermal lineage induction.

**De novo Jmjd2c recruitment to H3K4me1/me2-rich lineage-specific enhancers in primed embryonic stem cells**

We have shown that *Jmjd2c* loss in ESCs is sufficient to inhibit somatic differentiation, despite *Jmjd2c* being normally downregulated upon induction (Fig. 1E, upper panel). This suggests an important role for *Jmjd2c* in undifferentiated ESCs either in preserving their multi-lineage potential or in mediating the transition from pluripotent ESC to differentiated states. To address the molecular basis for the skewed differentiation of *Jmjd2c*-knockout ESCs, we mapped and compared *Jmjd2c* DNA-binding sites by ChIP-seq in naïve (2i/LIF) and primed (serum/LIF) ESCs (Marks et al., 2012). For this, E14-ESC clones stably expressing Flag-tagged *Jmjd2c* were generated (ESC<sup>FV-Jmjd2c-WT</sup>, Fig. S7), and expanded in either condition prior to anti-Flag ChIP (Fig. S8A-B).

In 2i/LIF, over 70% of *Jmjd2c* peaks were detected within 1kb from transcriptional start sites (TSS) (Fig. 3A) as previously reported (Pedersen et al., 2014). Strikingly, however, *Jmjd2c* genomic distribution was altered during the priming of ESCs for differentiation. Substantially more *Jmjd2c* peaks (45,485 vs. 20,377; FDR<0.0001) were detected in serum/LIF relative to 2i/LIF conditions. Moreover, we found that the majority of the peaks specific to the serum/LIF state were located more than 1kb away from the TSS interval hereafter referred to as distal peaks (Fig. 3A and Fig. S8C). This trend was
recapitulated by interrogating an independent ChIP-seq dataset (Fig. S8D) (Das et al., 2014). Importantly, we identified that the sets of genes targeted by Jmjd2c in the two ESC states were largely overlapping as revealed using gene annotation analysis (Fig. 3B). Hence, these findings uncover that, in 2i/LIF, Jmjd2c primarily binds to TSS regions, yet additionally occupies distal regions affiliated with the same cohort of genes in serum/LIF, as further validated at selected (Fgf5 and Brachyury) loci by ChIP-qPCR on endogenous Jmjd2c protein in naïve (2i/LIF) and primed (serum/LIF) wild-type and Jmjd2c-knockout ESCs (Fig. S8E-G).

Jmjd2c-bound distal peaks most closely overlapped with H3K4me1-rich sites (Fig. 3C), which typically define enhancers (Creyghton et al., 2010; Zentner et al., 2011). As expected, Jmjd2c-bound TSS regions were preferentially decorated with H3K4me3, while H3K4me2 could be detected at both TSS and distal peaks. Given that Jmjd2c can bind both H3K4me2 and H3K4me3 in a Tudor domain-dependent manner (Pedersen et al., 2014), we asked whether Jmjd2c recruitment at enhancers might be at least partly mediated via H3K4me2 recognition. Combining mutagenesis and ChIP-qPCR analyses, we showed that Jmjd2c binding was abrogated at TSS and distal regions in ESCs expressing a mutant version of Jmjd2c lacking its two Tudor domains (ESCs$^{FV-Jmjd2c-\Delta T}$) (Fig. 3D and Fig. S7D), indirectly validating H3K4-dependent Jmjd2c DNA-binding. Strikingly, however, FV-Jmjd2c-\Delta T binding was selectively retained at ESC-specific (Esrrb and Klf4) enhancers (Fig. 3D, bottom panel), suggesting a different mode of Jmjd2c recruitment at these sites possibly via cooperation with additional enhancer-bound proteins including Jmjd2b and Nanog as previously suggested (Das et al., 2014).

Active and poised enhancers can be distinguished genome-wide by the presence or absence of p300-mediated H3K27ac marks (Creyghton et al., 2010; Zentner et al., 2011). Interestingly, we found that 85% of Jmjd2c-bound distal peaks harboured low or no H3K27ac deposition (Fig. 3E), indicating that Jmjd2c is prevalently recruited to poised enhancers in serum/LIF. Known motif sequence enrichment analysis at these sites disclosed a high incidence of motifs for differentiation-associated factors such as Brachyury, Gata3 and Atoh1 (Fig. 3F), typifying tissue-specific enhancers activated later on during development. Concordantly, Gene Ontology analysis revealed significant
enrichment for developmental and somatic differentiation processes at Jmjd2c-bound, H3K27ac-low sites (Fig. 3G). These findings corroborate with a role for Jmjd2c in promoting differentiation into derivatives of the three primary germ layers. Taken together, our findings reveal that Jmjd2c is recruited in a timely manner to lineage-specific enhancers during ESC priming for differentiation.

**The antagonistic enzymes Jmjd2c and G9a are co-enriched at active and poised enhancers independently of H3K9-modifying activities**

Consistent with its H3K9-demethylase activity (Cloos et al., 2006; Whetstine et al., 2006), we showed that constitutively depleting Jmjd2c in ESCs leads to a noticeable increase in bulk H3K9me2 levels (Fig. 1B and Fig. S1D). Deposition of H3K9 and DNA methylation are known mechanisms operating in extra-embryonic tissues and derived stem cells to prevent the expression of somatic, lineage-specific genes (Alder et al., 2010; Senner et al., 2012). In the light of Jmjd2c-knockout ESC skewed differentiation towards extra-embryonic fates, we thus asked whether Jmjd2c occupancy might antagonize the acquisition of repressive marks in pluripotent stem cells.

At the chromosomal level, G9a-mediated H3K9me2 deposition encompasses large domains yet is depleted at the TSS regions of active and lineage-specific genes in ESCs (Lienert et al., 2011). We confirmed genome-wide that Jmjd2c and H3K9me2 are mutually exclusive across Jmjd2c-bound TSS regions, while G9a and H3K9me2 are confined to regions flanking Jmjd2c peak summits, as demonstrated using heatmap distributions and Pearson’s correlation coefficients (Fig. 4A-B, left panels). In striking contrast, however, Jmjd2c and G9a largely overlapped across enhancer regions in the absence of H3K9me2 deposition (Fig. 4A-B, right panels), as observed at both active and poised Jmjd2c-bound distal sites (Fig. S9). The co-localisation of the two antagonistic enzymes Jmjd2c and G9a at enhancers suggests a possible counter-acting mechanism in the control of gene expression. Loss of Jmjd2c, however, did not lead to increased levels of H3K9me2 and de novo DNA methylation (Fig. 4C; data not shown), as examined at the locus level across Fgf5 and Brachyury regulatory regions in Jmjd2c-knockout ESCs, and in derived cEpiSCs and induced-mesodermal progenitors where Fgf5 and
Brachyury activation is respectively inhibited in the absence of Jmjd2c (Fig. 2). These data strongly suggest that, in contrast to what we hypothesized, the failure of Jmjd2c-knockout cells to differentiate towards somatic derivatives is not due to a lack of Jmjd2c-mediated protection against the acquisition of repressive marks at Jmjd2c-bound gene targets.

Surprisingly, we found that G9a highest enrichment levels were detected at active (H3K27ac-high) Jmjd2c-bound distal sites (Fig. S10A, left panel), as exemplified at Esrrb and Klf4 loci (Fig. S10B-C). Moreover, G9a significantly overlapped with known enhancer-associated factors including p300, Oct4 and the subunits of Mediator (Med1) and Cohesin (Smc1a) complexes at these sites in ESCs (Fig. 5A-B). Lower yet detectable G9a enrichment, with peaks closely aligned with Jmjd2c, p300, Oct4, Med1 and Smc1a, also marked poised (H3K27ac-low) Jmjd2c-bound enhancers (Fig. 5A, lower panels), as illustrated at Fgf5 and Brachyury loci (Fig. S10D-E). The detection of differential G9a enrichment levels at ESC-specific and transcriptionally primed loci was furthermore verified by ChIP-qPCR in JM8-ESCs (Fig. 5C), and validated in control and G9a-knockout ESCs where G9a precipitation was abolished as expected (Fig. S11A-C). Interestingly, whilst Jmjd2c binding remained unaltered in G9a-knockout ESCs, G9a was lost at Fgf5 and Brachyury enhancers in the absence of Jmjd2c (Fig. S11D), suggesting a possible role for Jmjd2c in facilitating G9a binding. Jmjd2c-G9a co-occupancy was furthermore supported by the identification of physical interaction between Jmjd2c and G9a/GLP (Fig. 5D), and their simultaneous detection at the same enhancer fragments in sequential ChIP (re-ChIP) assays (Fig. S11E). Importantly, Jmjd2c and G9a also interact with Med1 (Fig. S11F-G), further implying that Jmjd2c-G9a co-occupancy might coincide with the assembly of activating protein mega-complexes at enhancers. Taken together, our findings unveil Jmjd2c and G9a as novel enhancer-associated factors, and demonstrate that these molecules are co-recruited genome-wide to active and poised enhancers in ESCs independently of their H3K9-modifying activities.
**Jmjd2c facilitates the assembly of essential enhancer-protein complexes in ESC-derived epiblast stem cells**

We uncovered that, similarly to H3K4me1, Jmjd2c pre-marks a large panel of tissue-specific enhancers in ESCs prior to gene activation and lineage specification (Fig. 3). We therefore hypothesized that, instead of protecting regulatory regions from the acquisition of repressive marks, Jmjd2c might facilitate and/or stabilize the assembly of enhancer-associated proteins including G9a at the onset of differentiation. To explore this, we compared the enrichment profiles of Jmjd2c, p300, Oct4, G9a, Med1 and Smc1a in Jmjd2c-knockout and wild-type ESC-derived cEpiSCs by ChIP-qPCR. For this analysis, we focussed on previously delineated Fgf5 poised (PE) enhancer in ESCs, or newly established (E1 and E3) enhancers upon Fgf5 activation in post-implantation epiblast-like cells (Fig. 6A) (Buecker et al., 2014) where these sites are co-occupied by Jmjd2c and G9a as verified in wild-type cEpiSCs (Fig. 6B, left panel).

All three Fgf5 enhancer (PE, E1 and E3) elements examined were similarly bound by Oct4 and p300, and harboured high levels of p300-mediated H3K27ac deposition in wild-type and Jmjd2c-knockout cEpiSCs (Fig. 6B; data not shown). This suggests that Jmjd2c is not required for the binding of the pioneer transcription factor Oct4 and/or the establishment of permissive chromatin at enhancers. Despite similar detection of protein levels in wild-type and knockout samples (Fig. S12A), we observed that Jmjd2c loss abrogated G9a recruitment as seen at the ESC stage (Fig. S11D, right panel), and furthermore destabilized the loading of the essential enhancer-associated factors Med1 and Smc1a (Fig. 6B), potentially impeding Fgf5 expression in Jmjd2c-knockout cEpiSCs (Fig. S5A). Remarkably, we identified that G9a, Med1 and Smc1a binding were similarly compromised at poised enhancers of germ layer (Zic1 and Brachyury) markers prior to gene activation (Fig. S12B). Based on these findings, we propose that inefficient assembly of activating protein complexes at poised and newly established enhancers could account for the impaired activation of lineage-affiliated genes that we have observed upon somatic differentiation in Jmjd2c-knockout pluripotent stem cells (Fig. 1E and Fig. 2).
Discussion

In this study, we have identified a novel regulatory function for Jmjd2c at tissue-specific enhancers during ESC priming for differentiation. We show that Jmjd2c is required for successful multi-lineage differentiation as assessed upon EB formation. In the absence of Jmjd2c, EBs exhibited reduced size and ineffective induction of differentiation-associated genes including early markers of all three mesoderm, endoderm and ectoderm lineages. Moreover, we established that ESC differentiation was impeded or stalled at an early post-implantation epiblast-like stage. Indeed, while Jmjd2c-knockout ESCs could transit into self-renewing cEpiSCs, these cells failed to establish a functionally primed state; a point that was here reinforced by their inability to further progress into mesodermal progenitors. In contrast, we found that Jmjd2c-knockout ESCs could readily differentiate into primitive endoderm-like derivatives under permissive conditions, as recently confirmed in triple Jmjd2abc knockout models (Pedersen et al., 2016). Interestingly, however, amongst the three Jmjd2 family members, Jmjd2c is uniquely downregulated in the primitive endoderm of the developing blastocyst, while being upregulated in the epiblast at peri-implantation times (Fig. S3) (Boroviak et al., 2015). This in vivo expression pattern most closely concurs with a primary role for Jmjd2c in the epiblast, while being dispensable for the formation of extra-embryonic tissues, as demonstrated in this study using ESC, EpiSC and XEN in vitro models.

We confirmed that Jmjd2c knockout is not detrimental to ESC proliferation and the maintenance of an undifferentiated phenotype upon prolonged culture (Pedersen et al., 2014); a conclusion here extended to ESC-derived EpiSCs. These results reiterate the robustness of pluripotent stem cell self-renewal, most likely reflecting compensation mechanisms amongst related transcriptional regulators including Jmjd2 family members (Pedersen et al., 2016). These results, however, contrast with earlier studies showing that shRNA-mediated Jmjd2c depletion led to spontaneous ESC differentiation and/or de-repression of many lineage-specific markers (Das et al., 2014; Loh et al., 2007). The discrepancies between these differing phenotypes could relate to differences in genetic backgrounds, culture conditions and the use of different knockdown constructs versus the study of
constitutive knockout ESC models. Importantly, our conclusion that Jmjd2c-depleted ESCs self-renew normally yet fail to properly differentiate into epiblast-derived progenitors is based on concurring functional characterisation of Jmjd2c knockout and knockdown models, thus ruling out off target effects commonly associated with shRNA approaches. Previously published studies of Jmjd2c function in ESCs (Das et al., 2014; Loh et al., 2007; Pedersen et al., 2014) did not investigate the impact of Jmjd2c depletion on the differentiation abilities of ESCs upon EB formation and lineage-specific induction, which precludes further comparison.

Interestingly, ectopically expressing Jmjd2c in ESCs also led to differentiation inhibition upon EB formation (data not shown). This finding together with Jmjd2c being normally downregulated during this process points to an important role at the onset of differentiation. Accordingly, we uncovered that Jmjd2c is recruited in a timely manner to lineage-specific enhancers upon ESC priming for differentiation. By directly comparing Jmjd2c genome-wide DNA-binding sites in 2i/LIF and serum/LIF, we confirmed that Jmjd2c is prevalently bound to H3K4me3-rich TSS regions of active and differentiation-associated genes in 2i/LIF. Strikingly, however, we identified that a significant fraction of serum/LIF-specific Jmjd2c binding sites maps away from TSS regions, overlapping with H3K4me1/me2-rich enhancers regions in the vicinity of the same cohort of gene targets. While Jmjd2c binding is less abundant at distal relative to TSS sites (Fig. S10), we validated that Jmjd2c is similarly recruited, at least in part, to enhancers and cognate promoters via its Tudor domains, most likely by recognition of H3K4me2/1 and H3K4me3, respectively (Pedersen et al., 2014). This corroborates with Jmjd2c detection in H3K4me3 and H3K4me1-coupled proteome datasets, as recently reported (Engelen et al., 2015). Given that regulatory regions nucleate the binding of numerous transcriptional regulators and co-factors, resident molecules might also contribute to Jmjd2c recruitment via protein-protein interaction at these sites.

Remarkably, however, Jmjd2c was found similarly enriched at active and pre-marked (poised) enhancers in serum/LIF (Fig. 5), suggesting that Jmjd2c could act as molecular platform for the recruitment of enhancer constituents. In particular, we asked whether the loss of Jmjd2c in ESCs...
might impact on Oct4 and p300 re-distribution at newly activated (Fgf5) enhancer sites upon ESC-to-EpiSC conversion. Binding of Oct4, p300 and p300-mediated H3K27ac deposition were, however, retained at Fgf5 in Jmjd2c-knockout cEpiSCs. Instead, we established that Jmjd2c was required for the proper binding of Med1 and Smc1a at active (Fgf5) and poised enhancers in epiblast-like cells (Fig. 6 and Fig. S12). A facilitating role for Jmjd2c in the assembly of activating enhancer-protein complexes was also supported by the ability of Jmjd2c to physically interact with G9a and Med1 in ESCs. Together these findings suggest that, in the absence of Jmjd2c, inefficient loading of essential Mediator-Cohesin complexes at lineage-specific enhancers impairs the activation of affiliated genes, accounting for the differentiation defect observed in Jmjd2c-knockout cells.

Given the established role of Mediator and Cohesin in bridging enhancers and core promoters (Kagey et al., 2010), we speculate that Jmjd2c recruitment to enhancers might coincide and/or contribute to DNA looping events prior to gene activation and lineage specification (Fig. 7). In line with this model, we find that Jmjd2c-bound distal peaks closely align with promoter-enhancer interaction sites as shown in the vicinity of Foxa2 in ESCs (Fig. S13). Interestingly, we note that the stability of all Jmjd2c-bound promoter-enhancer interactions observed across the genome is significantly enhanced in serum/LIF when compared to 2i/LIF (CHiCAGO score analysis, \( P\)-value \(2.446 \times 10^{-12}\); O. Joshi, H.G. Stunnenberg, unpublished), correlating with Jmjd2c re-distribution to poised enhancers during ESC priming for differentiation. However, and given that ChIP and Hi-C approaches commonly employ cross-linked chromatin, it remains unclear whether Jmjd2c enhanced detection at enhancers might be the cause or the result of stabilized promoter-enhancer interactions in serum/LIF.

An intriguing finding arising from this study is the co-recruitment of the H3K9-methyltransferase G9a to Jmjd2c-bound distal peaks in ESCs. Contrasting with its canonical role in gene silencing (Feldman et al., 2006; Mozzetta et al., 2014), highest G9a co-enrichment levels were unexpectedly observed at ESC-specific, Jmjd2c-bound enhancers, suggesting that G9a/Jmjd2c co-enrichment might coincide with the formation of activating complexes. Moreover, and similar to Oct4, p300, Med1 and Smc1a, G9a was
also present at lineage-specific, Jmjd2c-bound enhancers though at reduced levels in ESCs. In the absence of Jmjd2c, G9a binding was destabilized, as also demonstrated in ESC-derived cEpiSCs along with Med1 and Smc1a. Interestingly, G9a was found capable of interacting with Jmjd2c, Med1 or CDYL, suggesting that G9a can form both activating and repressive complexes in ESCs (Fritsch et al., 2010). This is in agreement with previous reports showing that G9a is co-recruited and interacts with either the co-activator Med1 or the co-repressor Jarid1 in a mutually exclusive manner at β-globin genes during haematopoiesis (Chaturvedi et al., 2012; Shankar et al., 2013). Remarkably, and consistent with a dual role for G9a in regulating gene expression, we find that Jmjd2c-G9a co-bound targets are significantly enriched amongst differentially expressed genes in G9a-knockout ESCs (Mozzetta et al., 2014) and E8.5 embryos (Auclair et al., 2016), showing clear evidence for both gene upregulation and downregulation in vitro and in vivo (Fig. S14). Notably, genes associated with developmental processes are prevalently downregulated in E8.5 embryos in the absence of G9a as previously documented (Auclair et al., 2016; Mozzetta et al., 2014). The mechanisms underlying G9a action as repressor and activator in ESCs and in other cellular contexts (Chaturvedi et al., 2012; Shankar et al., 2013) remain, however, unknown.

Despite a global increase in H3K9me2 levels in the absence of Jmjd2c, we did not detect any aberrant acquisition of H3K9 and DNA methylation at Jmjd2c/G9a co-bound lineage-affiliated genes in Jmjd2c-knockout ESCs, cEpiSCs and upon lineage specification (Fig. 4; data not shown). This argued against a role for Jmjd2c in continually removing G9a-mediated H3K9me2 deposition, implying novel histone-independent roles for Jmjd2c and G9a at tissue-specific enhancers. While the precise molecular interplays between the two molecules need to be fully deciphered, we note that G9a automethylation sites, which anchor the binding of repressive complexes (Ruan et al., 2012), were previously identified as potential targets for Jmjd2c-mediated demethylation (Ponnaluri et al., 2009). Whether demethylation of G9a by Jmjd2c via its catalytic domain is a prerequisite for interaction with activating complexes needs to be studied. More generally, further elucidating how
Jmjd2c and other histone demethylases might act as key post-translational regulators to promote the assembly of activating enhancer-protein complexes could indeed provide novel important insights into the regulation of enhancer activity and gene expression in stem cells and development.

Materials and Methods

Cell Culture
Mouse ESCs were cultured as previously described (Alder et al., 2010) with 10% FBS (serum), LIF or adapted to serum-free conditions (N2B27 with 1μM PD0325901, 3μM CHIR99021 and LIF) as described (Ying et al., 2008). Generation of ESC lines are described in Supplementary Information. ESC differentiation was induced in embryoid bodies (EBs) (ultra-low attachment plates, Corning, in 5% FBS without LIF) or with addition of 1 μM all-trans retinoic-acid (atRA) in 5% FBS without LIF. For mesoderm differentiation, EpiSCs were cultured in FLyB media (bFgf, LY294002 and BMP4) for 36 hours followed by either FB40 (bFgf and BMP4) or FLyWLDN (bFgf, LY294002, Wnt3a and LDN193189) media as previously described (Cheung et al., 2012). Full media composition and generation of cEpiSCs are outlined in Supplementary Information.

Quantitative PCR
RNA was isolated with the RNeasy mini kit (Qiagen) and reverse-transcribed using SuperScript II (Invitrogen). cDNA/DNA was amplified with KicQstart SYBR Green PCR Mastermix (Sigma). Details and primers sequences are listed in Supplementary Information.

Immunofluorescence staining
Cells fixed with 4% paraformaldehyde were permeabilized/blockaded for 30 minutes on 0.4% TritonX-100 and 10% serum. Primary antibody (Supplementary Information) incubation occurred overnight at 4°C. Fluorophore-conjugated secondary antibodies (ThermoFisher) were incubated for 1 hour. Fluorescence was visualised on a SP5 Leica confocal microscope or a fluorescent/brightfield microscope.
Immunoblotting, IP, ChIP and ChIP-seq

Whole-cell lysates and acid-extracted histones (Shechter et al., 2007) were resolved on SDS-PAGE gels and transferred into PVDF membranes (GE Healthcare). Immunoprecipitation (IP) and chromatin immunoprecipitation (ChIP) was performed as previously described (Battisti et al., 2016; Frank et al., 2001; Fritsch et al., 2010). Experimental details and information about computational analysis are outlined in Supplementary Information.

Accession numbers

ChIP-seq data is deposited into Gene Expression Omnibus under the accession number xx.
Acknowledgements
We are grateful to Huck-Hui Ng for antibodies and shRNA vectors; William Skarnes, Jennifer Nichols, Roger Pedersen and Janet Rossant for cell lines; Raymond Poot and Ian Chambers for plasmids; and Fabrice Lavial, Sergio German, Anne Helness, Julien Pontis, Van Nguyen, Vincent Brochard, and Shuangyin Wang for their technical and bioinformatics assistance. Thanks to the Advanced Sequencing Facility at the Francis Crick Institute. Thanks also to Wei Cui, Alice Jouneau and Tristan Rodriguez for discussions and/or critical reading of the manuscript.

Competing interests
The authors declare that they have no conflict of interest.

Author contribution
R.A.T. conducted most of the experiments; J.L.H. and H.F.J. performed mesoderm differentiations; D.K. and L.W. conducted knockdown and rescue experiments; L.F. and S.A. conducted co-immunoprecipitation experiments and advised on G9a ChIP; T.B-K. performed anti-Flag ChIP; E.B. and E.C. analysed ChIP/RNA-seq datasets; I.V.T. and K.K.N. assisted on bioinformatics and ESC-to-XEN cell conversion; C.F. generated Jmjd2c-knockout ESCs; O.J. and H.G.S. performed ChiCAGO analyses on unpublished Hi-C capture datasets; R.A.T. and V.A. prepared the manuscript, and V.A. conceived the project.

Funding
This work was supported by the FCT-Portugal (SFRH/BD/70242/2010), GRT (P55000), BHF (PG/12/86/29930), IC-PhD Scholarship (STU0082882), CNRS, MRC (MR/K00090X/1 and MR/K500793/1), Wellcome Trust Sanger Institute, Francis Crick Institute, ERC grant ERC-2013-AdG No.339431-SysStemCell, and Imperial College London.
References


Fig. 1. *Jmjd2c*-knockout ESCs can self-renew but fail to differentiate into somatic lineages. (A) Western blot using anti-*Jmjd2c* and anti-*Jmjd2b* antibodies of whole-cell extracts from wild-type (WT) JM8-ESCs and *Jmjd2c*-knockout (*Jmjd2c*-KO) cell lines (E2 and E3). α-Tubulin is used as loading control. (B) Western blots showing bulk levels of H3K9me2, H3K9me3 and total histone H3 in acid-extracted histone lysates from WT and *Jmjd2c*-KO cells. Signal quantification is presented relative to WT. (C) Ability of WT and *Jmjd2c*-KO cells to self-renew. Cells were plated at low density and cultured
for 5 days with LIF. Colonies were scored as undifferentiated, mixed or differentiated based on alkaline phosphatase activity. Data represents mean±s.e.m. of four experiments. (D) Phase-contrast images of day 9 embryoid bodies (EBs) formed from WT and Jmjd2c-KO (E3) ESCs. Bars, 100µm. (E) Expression profiling of Jmjd2c, pluripotency-associated (Nanog, Oct4), epiblast (Fgf5), mesoderm (Brachyury, Mixl1), endoderm (Foxa2), and neuroectoderm (Mash1, Pax3) markers during EB-mediated differentiation as assessed by RT-qPCR and normalized to housekeeping genes. Data represents mean±s.e.m. of at least three experiments. *P<0.05; Mann-Whitney U test at peak time-points. (F) Immunofluorescence staining for Oct4 (green), Gata6 (yellow) and Phalloidin (red) in WT and Jmjd2c-KO (E3) ESCs maintained in proliferative conditions or upon 1µM retinoic acid (atRA) addition and LIF removal for 4 days. Bars, 100µm. (G) Transcript levels of Gata6, Gata4, Sox7 and Dab2 (PrE markers), Jmjd2c and Fgf5 as assessed during atRA-induced differentiation. Expression is normalized to housekeeping genes and expressed as mean±s.e.m. of three experiments. *P<0.05; Mann-Whitney U test at day 4.
Fig. 2. Skewed differentiation of Jmjd2c-knockout cEpiSCs upon mesoderm induction. (A) Timeline of EpiSC induction towards early mesodermal (EM) progenitors and mature lateral plate (LPM) and paraxial (PM) mesoderm cells. (B) Expression levels of Fgf5 and Brachyury in control embryo-derived EpiSCs (grey), WT (black) and Jmjd2c-KO (red) cEpiSCs upon EM induction. Data is normalized to housekeeping genes and expressed relative to control EpiSCs as mean±s.e.m. of three experiments. *P<0.05; Mann-Whitney U test. (C) Average percentage (±s.e.m.) of Flk-1 positive LPM and Pdgfra positive PM differentiated cells, as monitored by flow cytometry in control, WT and Jmjd2c-KO cultures at day 4 post-induction in at least three experiments. (D) Expression of lateral plate (Kdr/Flk-1 and Isl1), paraxial (Pdgfra and Meox1) mesoderm, and extra-embryonic endoderm (Lrp2 and Sparc), definitive (Cxcr4) and pan (Foxa2) endoderm markers in WT and Jmjd2c-KO differentiated cells under LPM/PM conditions. Data is normalized to housekeeping genes and expressed relative to WT (day 0) as mean±s.e.m. of three experiments. *P<0.05; Mann-Whitney U test. (E) Phase-contrast images of LPM and PM WT and Jmjd2c-KO cultures. Bars, 100µm.
Fig. 3. Jmjd2c preferentially overlaps with H3K4me1/me2-rich lineage-specific enhancers in primed ESCs. (A) Numbers of Jmjd2c peaks located within 1Kb of transcriptional start sites (TSS) or outside this interval (Distal) in 2i/LIF and serum/LIF. (B) Venn diagrams indicating the overlap of Jmjd2c-
bound TSS and distal peaks in serum/LIF with at least one peak in 2i/LIF (min. overlap = 1bp); overlap of the nearest gene to Jmjd2c peaks in the two conditions (right panel). (C) Density heatmaps of H3K4me3/2/1 and Jmjd2c levels across a 10Kb window centred at TSS and Distal Jmjd2c-bound regions in serum/LIF. (D) Enrichment levels for full-length (FV-Jmjd2c-WT) and a mutant Jmjd2c form lacking Tudor domains (FV-Jmjd2c-ΔT) at TSS and enhancer sites of active (Esrrb and Klf4) and lineage-specific (Fgf5 and Brachyury) genes in ESCs. Fold enrichment is relative to control cells (empty vector; dotted line). Data represents mean±s.e.m. of three experiments. Background level is confirmed at an intergenic region. (E) Average density plots and heatmaps of H3K27ac, H3K4me1 and Jmjd2c levels across a 10Kb window centred at Jmjd2c-bound distal sites in serum/LIF. Peaks are sorted according to H3K27ac levels using a k-means clustering algorithm. (F) Motifs identified among overrepresented binding sequences at H3K27ac-low Jmjd2c distal peaks. (G) Top 10 most significant biological functions of genes associated with H3K27ac-low Jmjd2c distal peaks.
Fig. 4. G9a is enriched at distal Jmjd2c-bound sites independently of its H3K9-modifying activity. (A) Heatmap distributions (i.e. binned mean ChIP-seq read density) of Jmjd2c, G9a (Mozetta et al., 2014), H3K9me2 (1) (Liu et al., 2015) and H3K9me2 (2) (Das et al., 2014) across Jmjd2c-bound TSS and distal sites. Each ChIP-seq experiment is adjusted for sequencing depth and normalised to respective input. Colour key indicates enrichment levels from low to high. (B) Heatmap showing Pearson correlation between Jmjd2c, G9a and H3K9me2 distributions across Jmjd2c-bound TSS and distal sites. Colour key indicates correlation coefficient from low to high. (C) Enrichment levels for H3K9me2 at TSS, distal/enhancer and Jmjd2c-free flanking regions of Fgf5 and Brachyury as determined by ChIP-qPCR in WT and Jmjd2c-KO ESCs, cEpiSCs and upon cEpiSC mesodermal induction. Data is relative to flanking regions (dotted line) and shown as mean±s.e.m. of three experiments. Magea2 TSS is used as positive control.
Fig. 5. Jmjd2c and G9a co-occupy active and poised enhancers in ESCs.

(A) Average density plots and heatmaps showing enrichment levels for Jmjd2c, G9a, p300, Oct4, Med1 and Smc1a within a 10Kb window centred at H3K27ac-high (light blue) and H3K27ac-low (dark blue) Jmjd2c distal peaks. Scales are adjusted to maximum peak intensity for each dataset. (B) G9a peaks intersecting with Jmjd2c-distal H3K27ac-high sites are selected for this analysis. Depicted are the numbers of G9a/Jmjd2c peaks overlapping with Med1/p300, Med1/Oct4, and Med1/Smc1a (maximum gap 200bp). P-values
are calculated using hypergeometric tests. (C) Enrichment levels for H3K27ac, G9a and Med1 at enhancers of active (Esrrb and Klf4) and lineage-specific (Fgf5 and Brachyury) genes as assessed by ChIP-qPCR. Data is relative to an intergenic region (dotted line), and represents mean±s.e.m. of three experiments. (D) (Left) G9a and GLP immunoprecipitations performed in nuclear fractions of ESCs expressing Flag-tagged Jmjd2c (FV-Jmjd2c). Input corresponds to control ESCs. Lanes were cropped and repositioned for clarity. (Middle and right panels) GLP immunoprecipitation performed in nuclear fractions of WT, Jmjd2c-KO and full-length Jmjd2c Rescue ESCs. Interactions are visualised by immunoblotting (IB). Data represents duplicate experiments.
Fig. 6. Assembly of enhancer-protein complexes is destabilized in the absence of Jmjd2c in ESC-derived EpiSCs. (A) Mapping of poised (PE) and epiblast-specific enhancer sites (E1-E4) at Fgf5 locus (Buecker et al., 2014). (B) Enrichment levels for Jmjd2c, p300, Oct4, G9a, Med1 and Smc1a at indicated sites as assessed by ChIP-qPCR in WT and Jmjd2c-KO cEpiSCs. Fold enrichment is relative to an intergenic region (dotted line), and represents mean±s.e.m. of three experiments. *P<0.05; Mann-Whitney U test.
Fig. 7. Proposed model: Assembly of activating Jmjd2c-G9a centred enhancer-protein complexes. Jmjd2c and G9a co-occupy poised (lineage-specific) enhancers in primed ESCs where they stabilize the assembly of Mediator-Cohesin complexes (Kagey et al., 2010) necessary for the formation of DNA loops and potent gene activation at the exit of ESC pluripotent state and upon differentiation.
Jmjd2c/Kdm4c facilitates the assembly of essential enhancer-protein complexes at the onset of embryonic stem cell differentiation

Rute A. Tomaz, Jennifer L. Harman, Donja Karimlou, Lauren Weavers, Lauriane Fritsch, Tony Bou-Kheir, Emma Bell, Ignacio del Valle Torres, Kathy K. Niakan, Cynthia Fisher, Onkar Joshi, Hendrik G. Stunnenberg, Edward Curry, Slimane Ait-Si-Ali, Helle F. Jørgensen and Véronique Azuara

List of Supplementary Material

Figure S1 (related to Figure 1)
Figure S2 (related to Figure 1)
Figure S3 (related to Figure 1)
Figure S4 (related to Figure 1)
Figure S5 (related to Figure 2)
Figure S6 (related to Figure 2)
Figure S7 (related to Figure 3)
Figure S8 (related to Figure 3)
Figure S9 (related to Figure 4)
Figure S10 (related to Figure 5)
Figure S11 (related to Figure 5)
Figure S12 (related to Figure 6)
Figure S13 (related to Figure 7)
Figure S14 (related to Figure 7)
Table S1 (antibodies used in this study)
Table S2 (sequences of primers used for genotyping)
Table S3 (sequences of primers used for cloning)
Table S4 (sequences of primers used for RT-qPCR)
Table S5 (sequences of primers used for ChIP)
Table S6 (sequences of primers used for H3K9me2 ChIP)

Supplementary Materials and Methods
Supplementary References
**Fig.S1. Validation and characterization of Jmjd2c-knockout embryonic stem cell (ESC) clones.** (A) Scheme showing Jmjd2c targeted alleles. Black boxes indicate exons and red boxes the critical exon 9, white boxes splice acceptor sequences (SA) or polyadenylation sequences (pA), blue (tm1a allele) and green (tm2 allele) boxes drug resistance (neomycin (neo), hygromycin (hyg)) and marker (lacZ and GFP) genes, green circles and red triangles show FRT and loxP sites, respectively. Opposing arrows indicate the position of primer pairs used for genotyping. (B) EtBr agarose gel showing long range PCR products of genomic DNA of wild-type (WT) and homozygous Jmjd2c-knockout (Jmjd2c-KO) JM8-ESC clones (E2, E3) using primers indicated in (A). Fragment sizes are indicated in kilobases. (C) Anti-GFP labelling and DAPI staining of WT and Jmjd2c-KO ESC clones. Bars, 100 µm. (D) Western blot of acid-extracted histone lysates from WT and Jmjd2c-KO ESC clones (left panels) showing bulk levels of H3K9me2, H3K9me3, H3K36me3, H3K4me2, H3K27me3 and total H3. Western blot of acid-extracted histone lysates and whole cell extracts of Jmjd2c-KO ESC clone E3 transfected with an empty vector (Control) or with full-length Jmjd2c cDNA (Rescue) (right panels) showing bulk levels of H3K9me2, H3K9me3 and total H3 (upper lanes), and Jmjd2c, G9a and α-Tubulin (bottom lanes). (E) Relative expression levels of a panel of H3K9-demethylases (upper panel) and H3K9-methyltransferases (bottom panel) in WT and Jmjd2c-KO ESC clones grown in serum/LIF. (F) Growth curve of WT (ESC\textsuperscript{WT}) and Jmjd2c-KO (ESC\textsubscript{Jmjd2c-KO}) clones E2 and E3 in self-renewing conditions over 8 passages (16 days). Plot represents an average of the cell number scored in 3 independent experiments. Error bars indicate ±s.e.m. (G) Relative expression levels of the pluripotency-associated markers Oct4, Nanog, Esrrb, Klf4 and Tbx3 in WT and Jmjd2c-KO ESC clones. (H) Relative expression levels of differentiation markers associated to the trophectoderm (Cdx2 and Hand1), mesoderm (Brachyury and Mixl1), endoderm (Gata6 and Foxa2) and ectoderm (Math1 and Pax3) lineages in WT and Jmjd2c-KO ESC clones. All expression data were normalised to two housekeeping genes, and expressed relative to WT as the mean±s.e.m. of at least three biological replicates. *P<0.05; Mann-Whitney U test.
Fig. S2. Generation of embryoid bodies (EBs) is compromised in stable Jmjd2c-knockdown ESC clones. (A) E14-ESCs cells were transfected with two independent puromycin-selectable shRNA vectors targeting Jmjd2c (shJmjd2c #1 and #2) or a control vector (shLuc) targeting Luciferase (Loh et al., 2007). Selection was maintained for 4 days, then cells were fixed and stained for alkaline phosphatase activity. Bars, 100 µm. (B) Relative expression levels of Jmjd2 family members and selected pluripotency-associated factors in three stable Jmjd2c-knockdown clones established from transfected ESCs with shJmjd2c #1 vector. Data were normalised to housekeeping genes, and expressed relative to a control ESC clone (shLuc) as mean±s.e.m. of three biological replicates. *P<0.05; Mann-Whitney U test. (C) Western blot using anti-Jmjd2c antibodies on whole cell extracts of three stable Jmjd2c-knockdown ESC clones (shJmjd2c #1.1, #1.2 and #1.3) and a control clone (shLuc). α-Tubulin is used as loading control. (D) Percentage of colonies scored as undifferentiated (Undiff.), mixed or differentiated (Diff.) according to the intensity of alkaline phosphatase staining of stable Jmjd2c-knockdown and control ESC clones. Each cell line was plated at low density and cultured for 5 days with LIF and serum. Data are the mean±s.e.m. of three biological replicates. (E) Relative expression levels of differentiation markers associated to the trophectoderm (Cdx2 and Hand1), mesoderm (Brachyury and Mixl1), endoderm (Gata6 and Foxa2) and ectoderm (Math1 and Pax3) lineages in control (shLuc) and Jmjd2c-knockdown (shJmjd2c #1.1, #1.2 and #1.3) ESC clones. Data were normalised to two housekeeping genes, and expressed relative to a control ESC clone (shLuc) as mean±s.e.m. of three biological replicates. *P<0.05; Mann-Whitney U test. (F) Transcript levels of pluripotency-associated (Nanog and Oct4), Jmjd2c, and early differentiation markers for epiblast (Fgf5) and primitive streak (Brachyury and Mixl1) in shJmjd2c clone #1.3 and shLuc control ESCs upon EB-induced differentiation. Similar results were obtained in shJmjd2c clone #1.2 and #1.1 ESCs (data not shown). Data were normalized to two housekeeping genes, and expressed as the mean±s.e.m. of at least three independent experiments. *P<0.05; Mann-Whitney U test.
**Fig. S3.** *Jmjd2c* is dynamically expressed in the early mouse embryo. Comparative gene expression analysis at different developmental-times focussing on selected members of H3K9-demethylase families (*Jmjd2/Kdm4*: *Jmjd2a*, *Jmjd2b* and *Jmjd2c*; *Jmjd1/Kdm3*: *Jmjd1a* and *Jmjd1b*; *Kdm1*: *Lsd1* and *Lsd2*), epiblast (*Oct4* and *Nanog*) and primitive endoderm (*Gata6*) associated transcription factors, H3K9-methyltransferases (*G9a* and *GLP*) and the subunits of the Mediator (*Med1*) and Cohesin (*Smc1a*) complexes. Expression was assessed by RNA-seq in morula-stage embryos (E2.5), isolated inner cell mass (ICM) from early blastocysts (E3.5), dissected primitive endoderm (PrE) and epiblast layers from late blastocysts (E4.5) and in the post-implantation epiblast (E5.5), as previously published (Boroviak et al., 2015). Data are shown as the mean±s.d. of three independent pool samples in Fragments per Kilobase of Exon per Million Fragments (FPKM).
Fig. S4. Jmjd2c-knockout ESCs successfully generate self-renewing extra-embryonic endoderm (XEN) stem cells. (A-B) Timeline of ESC-to-XEN derivation protocol (adapted from Cho et al., 2012), and phase-contrast images of WT and Jmjd2c-KO ESC clone E3 cultures upon XEN cell conversion at the indicated time points. Bars, 100 µm. (C) Phase-contrast and staining for Gata4 and Dab2 of stably ESC-derived WT and Jmjd2c-KO converted XEN (cXEN) cells, and a control embryo-derived XEN cell line (IM8A). Bars, 100 µm. (D) Transcript levels of Nanog, Jmjd2c and XEN-associated markers (Gata6, Gata4, Sox17, Lama1, Sparc and Sox7) in WT and Jmjd2c-KO ESCs, cXEN cells, and embryo-derived XEN cells. Data were normalized to housekeeping genes, and expressed as the mean±s.e.m. of three biological replicates.
**Fig. S5.** *Jmjd2c*-knockout ESCs adopt an immature epiblast stem cell (EpiSC) phenotype.* (A) Transcript levels of epiblast (*Fgf5*, *Otx2*, and *Dnmt3b*), pluripotency (*Nanog*) and differentiation (*Brachyury* and *Foxa2*) markers upon conversion of WT and *Jmjd2c*-KO ESCs into EpiSCs (day 0 to 3) and in stably converted EpiSCs (cEpiSCs; day >30) in the presence of Activin and Fibroblast growth factor (AF). Data were normalized to housekeeping genes, and expressed as the mean±s.e.m. of at least three biological replicates. *P*<0.05; Mann-Whitney *U* test. (B) Phase-contrast images of stably derived cEpiSC cell lines from WT (cEpiSCWT) and *Jmjd2c*-KO (cEpiSC*Jmjd2c*-KO) clone E3 ESCs, and a control embryo-derived EpiSC line in which GFP expression is coupled with Oct4 (Oct4-GiP). Bars, 100 µm. (C) Oct4 labelling and DAPI staining in stable WT and *Jmjd2c*-KO cEpiSCs, and in control embryo-derived EpiSCsOct4-GiP. Bars, 100 µm.
Fig. S6. Skewed differentiation into extra-embryonic endoderm (XEN)-like phenotype upon mesodermal induction of Jmjd2c-knockout cEpiSCs. Phase-contrast images and E-cadherin labelling of WT and Jmjd2c-KO cEpiSCs at day 4 of differentiation into lateral plate (LPM) and paraxial (PM) mesoderm cell types (A), and of XENIM8A cells with and without BMP4 treatment (B). Bars, 100 µm.
Fig. S7. Characterization of ESC clones stably expressing double-tagged wild-type and mutant Jmjd2c proteins. (A) Scheme of generated Flag(x2)-V5 tagged full-length wild-type (FV-Jmjd2c-WT) and mutated (FV-Jmjd2c-ΔT) Jmjd2c construct where both Tudor domains were deleted. Both constructs were used to generate stable ESC lines. An empty version of the same construct (without Jmjd2c) was used to generate a control ESC line. (B) Western blot of whole cell extracts of independent FV-Jmjd2c-WT (clone#3 and #8) and control ESC clones showing Jmjd2c and Oct4 protein levels. Gapdh was used as a loading control. (C) Labelling of the Flag epitope or Oct4 (green), and DAPI staining (blue) in control and FV-Jmjd2c-WT clone#8 ESCs. Bars, 100 µm. (D) Western blot showing protein levels of the Flag epitope in FV-Jmjd2c-WT clone#3 (132 KDa) and FV-Jmjd2c-ΔT clone#1 (108 KDa) ESC lines. α-Tubulin was used as a loading control.
Development 144: doi:10.1242/dev.142489: Supplementary information

A

ESC<sub>Control</sub> 2i Serum ESC<sub>FV-Jmjd2c</sub> 2i Serum Jmjd2c α-Tubulin

B

Oct4 Fgf5

Expression

2i/LIF Serum/LIF 2i/LIF Serum/LIF

C

Jmjd2c peaks

Jmjd2c Input Oct4 p300

Jmjd2c peaks

Jmjd2c Input

Fgf5 Brachyury Foxa2

D

2i/LIF

This study Pedersen et al., 2014

Serum/LIF

This study Das et al., 2014

TSS Distal

E

2i/LIF Serum/LIF

Jmjd2c Enrichment

F

ESC<sub>WT</sub> ESC<sub>Jmjd2c-KO</sub>

Jmjd2c Enrichment

G

ESC<sub>WT</sub> ESC<sub>Jmjd2c-KO</sub>

Jmjd2c Enrichment
Fig. S8. Jmjd2c is re-distributed to lineage-specific enhancers during the priming of ESCs for differentiation. (A) Western blot showing Jmjd2c protein levels in control and FV-Jmjd2c-WT clone #8 ESCs cultured in either 2i/LIF or serum/LIF conditions. α-Tubulin was used as a loading control. (B) Expression of the pluripotency (Oct4) and early epiblast-associated (Fgf5) genes in control and FV-Jmjd2c-WT ESCs routinely cultured in 2i/LIF and serum/LIF showing the detection of Fgf5 transcript in primed (serum/LIF) ESC cultures in contrast to naïve (2i/LIF) cells. Data were normalized to housekeeping genes, and expressed as the mean±s.e.m. of three biological replicates. (C) ChIP-seq binding profiles showing Jmjd2c peaks at the TSS regions of the lineage-specific Fgf5, Brachyury and Foxa2 genes in 2i/LIF conditions (bottom panel), and the acquisition of additional Jmjd2c peaks overlapping with p300 and Oct4 at distal sites in the vicinity of the same genes in serum/LIF conditions (top panel). (D) Percentage of Jmjd2c-bound TSS (green) and distal (purple) peaks detected in primed (serum/LIF) and naive (2i/LIF) conditions using datasets generated in this study and in previously published reports as indicated. (E) Enrichment levels for endogenous Jmjd2c binding at TSS and distal (enhancer) regions of Fgf5 and Brachyury loci in formaldehyde-fixed chromatin from wild-type JM8-ESCs routinely cultured in 2i/LIF and serum/LIF conditions. Data were expressed as average fold enrichment over negative control region (intergenic; dotted line), and represent the mean±s.e.m. of three independent experiments. (F) Specificity of endogenous Jmjd2c ChIP was validated by assessing enrichment for Jmjd2c at active (Esrrb and Klf4) and poised (Fgf5 and Brachyury) TSS regions extracted from wild-type (WT) JM8-ESCs and Jmjd2c-knockout (Jmjd2c-KO) ESCs. Data were expressed as average fold enrichment over negative control region (intergenic; dotted line), and represent the mean±s.e.m. of three independent experiments. (G) Enrichment levels of endogenous Jmjd2c binding at distal regions of Fgf5 and Brachyury in WT versus Jmjd2c-KO ESCs. Data were expressed as average fold enrichment over negative control region (intergenic; dotted line), and represent the mean±s.e.m. of three independent experiments. *P<0.05; Mann-Whitney U test.
Fig. S9. G9a and Jmjd2c overlap genome-wide in ESCs at both active and poised enhancer regions in the absence of H3K9me2 deposition. (A) Heatmap representation of the distribution (i.e. binned mean ChIP-seq read density) of Jmjd2c (1: this study; 2: Das et al., 2014), G9a (Mozzetta et al., 2014), H3K9me2 (1: Liu et al., 2015; 2: Das et al., 2014) across Jmjd2c-bound TSS or active and poised distal sites. Each ChIP-seq experiment was adjusted for sequencing depth and normalised to their respective input. The colour key from blue to red indicates the enrichment levels from low to high, respectively. (B) Heatmap showing Pearson correlation between the distributions of Jmjd2c (1: this study; 2: Das et al., 2014), G9a (Mozzetta et al., 2014), H3K9me2 (1: Liu et al., 2015; 2: Das et al., 2014) across Jmjd2c-bound TSS or active and poised distal sites. The colour key from blue to red indicates the correlation coefficient from low to high, respectively.
Fig. S10. G9a highest density binding is observed at Jmjd2c-bound active enhancer regions in ESCs. (A) Coverage plot representation of the distribution (i.e. binned mean ChIP-seq read density) of G9a (Mozzetta et al., 2014) and Jmjd2c (1: this study; 2: Das et al., 2014) at Jmjd2c-bound TSS (green), distal active (light blue) and distal poised (dark blue) sites. Each ChIP-seq experiment was adjusted for sequencing depth and normalised to their respective input. (B) ChIP-seq binding profiles for G9a (Mozzetta et al., 2014) and Jmjd2c (1: this study; 2: Das et al., 2014), alongside with published profiles for the enhancer-associated factors p300, Oct4, Med1 and Smc1a, at the active enhancer regions of *Esrrb* (B) and *Klf4* (C) loci, and the poised enhancers of *Fgf5* (D) and *Brachyury* (D) loci. Red bars represent peaks called relative to respective input control samples for G9a (Mozzetta et al., 2014) and Jmjd2c (this study) ChIP-seq datasets.
Fig. S11. Jmjd2c facilitates G9a binding at lineage-specific enhancers in ESCs.

(A) Specificity of two anti-G9a antibodies (1: Cell Signalling; 2: R&D) was validated in ChIP-qPCR by assessing enrichment levels for G9a at previously reported regions with high (Vstm2l) and low (Nnat) enrichment in wild-type (WT) TT2-ESCs and G9a-knockout (G9a-KO) in serum/LIF conditions. Data were expressed as average fold enrichment over negative control region (intergenic; dotted line), and represent the mean±s.e.m. of three independent experiments. *P<0.05; Mann-Whitney U test. (B) Specificity of anti-G9a antibodies (1: Cell Signalling; 2: R&D) was also validated in ChIP-qPCR by assessing enrichment levels for G9a at the enhancer regions of active (Esrrb and Klf4) and transcriptionally primed (Fgf5 and Brachyury) genes in WT and G9a-KO ESCs in serum/LIF conditions. Data were expressed as average fold enrichment over negative control region (intergenic; dotted line), and represent the mean±s.e.m. of three independent experiments. *P<0.05; Mann-Whitney U test. (C) Western blot using anti-G9a, anti-GLP and anti-Jmjd2c antibodies of whole cell extracts from WT and G9a-KO ESCs. α-Tubulin was used as a loading control. (D) Enrichment levels for endogenous Jmjd2c at Fgf5 and Brachyury enhancer regions in WT and G9a-KO ESCs (left panel). Enrichment levels for G9a at Fgf5 and Brachyury enhancer regions in wild-type (WT) JM8-ESCs and Jmjd2c-knockout (Jmjd2c-KO) (right panel). Data were expressed as average fold enrichment over negative control region (intergenic; dotted line), and represent the mean±s.e.m. of three independent experiments. (E) Co-binding of Jmjd2c and G9a was validated at Fgf5 and Brachyury enhancer regions by sequential ChIP (Re-ChIP) in ESCs expressing Flag-tagged Jmjd2c. Jmjd2c was immunoprecipitated using anti-Flag antibodies, followed by immunoprecipitation with anti-G9a (R&D), IgG or beads only. An intergenic region was included to confirm background levels. Data were expressed as fold enrichment over beads only control (dotted line), and represent the mean±s.e.m. of three independent experiments. *P<0.05; Mann-Whitney U test. (F) G9a interaction partners were purified with a double immunoprecipitation (IP) with anti-Flag and anti-HA antibodies in soluble (S) and chromatin (C) nuclear fractions of HeLa cells expressing an empty vector (Control) or tagged (HF-G9a) G9a protein. (G) Med1 immunoprecipitation was performed in nuclear fractions of ESCs expressing a Flag-tagged Jmjd2c (FV-Jmjd2c). Interactions were visualised by immunoblotting (IB) with anti-Med1, anti-Jmjd2c or anti-CDYL antibodies. Data are representative of duplicate experiments. The input and IgG lanes of Jmjd2c correspond to the same experiment as Figure 5D.
Fig. S12. Loss of Jmjd2c compromises G9a, Med1 and Smc1a binding at Oct4-bound poised enhancers in ESC-derived cEpiSCs. (A) Western blot using antibodies against Jmjd2c, G9a, GLP, Med1, Smc1a, Oct4 and p300 in whole cell extracts from wild-type (WT) JM8-ESCs, Jmjd2c-knockout (Jmjd2c-KO) ESCs and derived cEpiSCs. α-Tubulin was used as a loading control. (B) Enrichment levels for Jmjd2c, p300, Oct4, G9a, Med1 and Smc1a at the active Fgf5 (PE) and poised Brachyury and Zic1 enhancers as assessed by ChIP-qPCR in WT and Jmjd2c-KO cEpiSCs. Data were expressed as average fold enrichment over negative control region (intergenic; dotted line), and represent the mean±s.e.m. of three independent experiments. *P<0.05; Mann-Whitney U test.
Fig. S13. Chromatin dynamics across Foxa2 locus in naïve (2i/LIF) and primed (serum/LIF) ESCs. ChIP-seq binding profiles showing p300, Oct4, H3K4me1 and Jmjd2c in either serum/LIF or 2i/LIF conditions across the Foxa2 locus (top panel). Interaction profile for the promoter of Foxa2 visualized for ESCs grown in either serum/LIF or 2i/LIF conditions (bottom panel). Pink arcs represent ESCs grown in either serum/LIF or 2i/LIF conditions. Pink arcs represent interactions from Foxa2 promoter identified using CHiCAGO pipeline (Cairns et al., 2015) based on newly generated high coverage capture Hi-C datasets (O. Joshi, H.G. Stunnenberg, unpublished). The depth of pink colour of each interaction arc represents the strength of the interaction.
Fig. S14. Jmjd2c-G9a co-bound developmental genes are downregulated in the embryo in the absence of G9a. (A) Enrichment of Jmjd2c-G9a regulated genes amongst genes differentially expressed in G9a-knockout ESCs and embryos at E8.5. Upregulated (log2 fold-change >0, q-value <0.05) and downregulated (log2 fold-change <0, q-value <0.05) genes were defined from publicly available RNA-seq datasets profiling gene expression in ESCs (GSE) and E8.5 embryos (GSE) with and without G9a knockout (Auclair et al., 2016; Mozzetta et al., 2014). Expected numbers in each set were calculated from the proportions of all measured genes belonging to each category (upregulated, downregulated, and none). Difference of observed numbers from expected were evaluated with Chi-squared test giving $P$-value = 3.10E-93 and 1.00E-83 in ESC and E8.5 embryo samples, respectively. (B) Top 10 most significant biological processes of Jmjd2c-G9a regulated genes that are either up (green) or downregulated (yellow) in G9a-knockout ESCs (left panel) or G9a-knockout embryos at E8.5 (right panel).
### Table S1. Antibodies used in this study

<table>
<thead>
<tr>
<th>Primary Antibody</th>
<th>Catalogue Number</th>
<th>Supplier</th>
<th>Concentration/Quantity</th>
<th>Western Blot</th>
<th>IF</th>
<th>ChIP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cdyl</td>
<td>ab5188</td>
<td>Abcam</td>
<td>1:1000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Dab2</td>
<td>sc13982</td>
<td>SantaCruz</td>
<td>-</td>
<td>1:250</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>E-Cadherin</td>
<td>U3254</td>
<td>Sigma-Aldrich</td>
<td>-</td>
<td>1:500</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Flag M2</td>
<td>F1804</td>
<td>Sigma-aldrith</td>
<td>1:1000</td>
<td>1:500</td>
<td>10 µg</td>
<td>0.24 µg</td>
</tr>
<tr>
<td>G9a</td>
<td>3306</td>
<td>Cell Signalling</td>
<td>1:1000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>G9a</td>
<td>PP-A8620A-00</td>
<td>R&amp;D</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5 µg</td>
</tr>
<tr>
<td>Gata4</td>
<td>sc-9053</td>
<td>SantaCruz</td>
<td>-</td>
<td>1:250</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gata6</td>
<td>AF1700</td>
<td>R&amp;D Systems</td>
<td>-</td>
<td>1:500</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>GFP</td>
<td>ab290</td>
<td>Abcam</td>
<td>-</td>
<td>1:1000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>GLP</td>
<td>PP-B0422-00</td>
<td>R&amp;D Systems</td>
<td>1:1000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>H3</td>
<td>ab1791</td>
<td>Abcam</td>
<td>1:50,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>H3K27ac</td>
<td>ab4729</td>
<td>Abcam</td>
<td>-</td>
<td>5 µg</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>H3K27me3</td>
<td>07-449</td>
<td>Millipore</td>
<td>1:100,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>H3K36me3</td>
<td>mAb-183-050</td>
<td>Diagenode</td>
<td>1:10,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>H3K4me2</td>
<td>07-030</td>
<td>Millipore</td>
<td>1:50,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>H3K9me2</td>
<td>ab1220</td>
<td>Abcam</td>
<td>1:20,000</td>
<td>2 µg</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>H3K9me3</td>
<td>ab8898</td>
<td>Abcam</td>
<td>1:100,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jmjd2b</td>
<td>A301-478A</td>
<td>Bethyl Laboratories</td>
<td>1:2000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jmjd2c</td>
<td>-</td>
<td>H.H. Ng’s lab</td>
<td>1:2000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jmjd2c</td>
<td>sc-104949</td>
<td>SantaCruz</td>
<td>1:1000</td>
<td>5 µg</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Med1</td>
<td>A300-793A</td>
<td>Bethyl Laboratories</td>
<td>1:1000</td>
<td>8 µg</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Oct4</td>
<td>sc-8628</td>
<td>SantaCruz</td>
<td>1:1000</td>
<td>5 µg</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Oct4</td>
<td>sc-5279</td>
<td>SantaCruz</td>
<td>-</td>
<td>1:200</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>p300</td>
<td>sc-585</td>
<td>SantaCruz</td>
<td>1:1000</td>
<td>5 µg</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Phalloidin</td>
<td>P1951</td>
<td>Sigma-Aldrich</td>
<td>-</td>
<td>1:100</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Smc1a</td>
<td>A300-055A</td>
<td>Bethyl Laboratories</td>
<td>1:1000</td>
<td>8 µg</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>α-Tubulin</td>
<td>T6074</td>
<td>Sigma-Aldrich</td>
<td>1:20,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Table S2. Sequences of primers used for genotyping

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence (5’ – 3’)</th>
<th>Allele</th>
</tr>
</thead>
<tbody>
<tr>
<td>tm1a-F</td>
<td>GAAGTAGGAGGAGAACCATAGTTCCAGAG</td>
<td>First</td>
</tr>
<tr>
<td>tm1a-R</td>
<td>GCCCTTTCGCTATTACGGCCAGCTG</td>
<td></td>
</tr>
<tr>
<td>tm2-F</td>
<td>AAGAGGTAAGAAGCCATCACATC</td>
<td>Second</td>
</tr>
<tr>
<td>tm2-R</td>
<td>GCAGCTATTTACCCCACGAGA</td>
<td></td>
</tr>
</tbody>
</table>

### Table S3. Sequences of primers used for cloning of Jmjd2c

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence (5’ – 3’)</th>
<th>Vector</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xhol-Jmjd2c-F</td>
<td>ATACATTCTCGAGATGGAGGTGTT</td>
<td>pPy-CAG-Jmjd2c</td>
</tr>
<tr>
<td>Pacl-Jmjd2c3-R</td>
<td>CTCTTTAATTACTACTGTCCTTCTGACACTT</td>
<td>FV-Jmjd2c-WT</td>
</tr>
<tr>
<td>BamHI-Jmjd2c-F</td>
<td>ATTAGGATCCGAGGTGGGAGGTG</td>
<td>FV-Jmjd2c-ΔT</td>
</tr>
<tr>
<td>Sall-Jmjd2c-R</td>
<td>TAATGTCGACCTACCGGTGGTTGAGGT</td>
<td></td>
</tr>
<tr>
<td>Sall-Del-Tudor-R</td>
<td>TAATGTCGACCTACCGGGTTTTGAGG</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Forward (5’ – 3’)</td>
<td>Reverse (5’ – 3’)</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Oct4</td>
<td>CGTGGAGACCTTGCGACGCCTG</td>
<td>GCTTGGAATCTGTCTAGCTCTCT</td>
</tr>
<tr>
<td>Brachyury</td>
<td>CCGGGTGCTAGGTAAGTTAATTGT</td>
<td>CTTCACTGGACCTGTGTTTGTT</td>
</tr>
<tr>
<td>Brachyury*</td>
<td>TCACAAAGTACAAACTCACC</td>
<td>TATAATCTGCTAGAAGACGACTC</td>
</tr>
<tr>
<td>Cxcr4</td>
<td>CCGAGTGAAGAATGACCCATT</td>
<td>ATGACCAAGGATACCAATTCA</td>
</tr>
<tr>
<td>Dnmt3b</td>
<td>TTTCTGAGCCCTGACCGACGAA</td>
<td>TCAGAAAGGCTGAGACTCCCCCTGCTT</td>
</tr>
<tr>
<td>Setb1</td>
<td>GAGCCGGGGAGAGGCTGGA</td>
<td>TAGCTGCTCGGGAAGCCTC</td>
</tr>
<tr>
<td>Esrrb</td>
<td>GCCCTGGGCTCTAGTTTC</td>
<td>TACAGTCCTCTAGCTCTCT</td>
</tr>
<tr>
<td>Fgf5</td>
<td>TGTGTTCCTAGGGATTGAG</td>
<td>ACTCATGCTCTGCTAGCTCT</td>
</tr>
<tr>
<td>Fgf5*</td>
<td>ACCTTTTCTCTGCTTCTGTG</td>
<td>TTTCTGCTGCTAGCTCT</td>
</tr>
<tr>
<td>Fk-1</td>
<td>GAGCGGAGAAGAGTCTGAG</td>
<td>TCAAGCTGCTCTGAGATGT</td>
</tr>
<tr>
<td>Foxa2</td>
<td>ACTGGAGACGTACTGAC</td>
<td>AGGATGACATGTCTAGATG</td>
</tr>
<tr>
<td>Foxa2*</td>
<td>GAGCCGGGATGGCTGAGA</td>
<td>AGGAGGAAAGAACAAAC</td>
</tr>
<tr>
<td>G9a</td>
<td>TCACCCCTCTGACACTGACAT</td>
<td>GCTCATCTCCACTAGTCTT</td>
</tr>
<tr>
<td>Gapdh</td>
<td>AGAGGTGTGGAAGCAGGAC</td>
<td>CGAGGGAGAGAGAGAG</td>
</tr>
<tr>
<td>Gata4</td>
<td>GACACCCCTGAGGCTGAGGCA</td>
<td>TTTCTGGAAGAACAGAGGAG</td>
</tr>
<tr>
<td>Gata6</td>
<td>GAGCTGCTGCTACCATAGAGA</td>
<td>TCGAAGGGCAAGCTACTTCTG</td>
</tr>
<tr>
<td>GLP</td>
<td>CAGATGGAGAAACAAATAGAC</td>
<td>TTGCTCTCCACTGCTCTGT</td>
</tr>
<tr>
<td>Hmbs</td>
<td>ACTGGTGAGGATATGGAGCTGAGCTAGATGAGC</td>
<td>GCCACGGATGCTGACCCCTCCGT</td>
</tr>
<tr>
<td>Isl1</td>
<td>AGACCCCTCTGACACTGACAT</td>
<td>GCTCATCTCCACTAGTCT</td>
</tr>
<tr>
<td>Jmjd1a</td>
<td>GAGCCACAGTGGAGACTC</td>
<td>TCTGCTCATGACATTCA</td>
</tr>
<tr>
<td>Jmjd2a</td>
<td>TTTGTGAAATCTCGGCTGTG</td>
<td>TACAGTCCTGAGTGAGAC</td>
</tr>
<tr>
<td>Jmjd2b</td>
<td>CATGTTGAGGACACGACTG</td>
<td>AAGGAGGATGGCAAGCCTCT</td>
</tr>
<tr>
<td>Jmjd2c</td>
<td>GATGACTGCGGCTTACGGGT</td>
<td>CCTCAACAGTGGCTGCT</td>
</tr>
<tr>
<td>Kif4</td>
<td>GTGCCCGCAGAATCCGACTGAGT</td>
<td>GTCGTTGAGCTCCAGCT</td>
</tr>
<tr>
<td>L19</td>
<td>TGGATCTGCGAGGATGAGA</td>
<td>GCCAGGGCAGTGGCTGAAAGAG</td>
</tr>
<tr>
<td>Lrp2</td>
<td>CCTGCTCGAGCTATGGAGA</td>
<td>GCTGAGGCTGAGACTGAGAG</td>
</tr>
<tr>
<td>Lsd1</td>
<td>GATGATGCTCTGGGAAAAGGAG</td>
<td>GGGCCAGGGATGAAATGAC</td>
</tr>
<tr>
<td>Math1</td>
<td>GAGGAAGGCTCTCGTGGCAGG</td>
<td>GGCAGAGTTGCTGAGATG</td>
</tr>
<tr>
<td>Meox1</td>
<td>CCGAGGAGAAGAATCTACCG</td>
<td>GAGATGTTGCTGAGAGAG</td>
</tr>
<tr>
<td>Mixl1</td>
<td>GACAGGACATGTACCAGAC</td>
<td>GCTTCAAACACCTAGCTCAG</td>
</tr>
<tr>
<td>Nanog</td>
<td>CCTACACAGGTTCTCTGCTA</td>
<td>TCTGGCTCTGGCAGAG</td>
</tr>
<tr>
<td>Otx2</td>
<td>TATCTAAAGAAGCAGCCGCTTACTG</td>
<td>AAGTCTTACACCGAGGAAATGTG</td>
</tr>
<tr>
<td>Pax3</td>
<td>GGGAACTGAGGGCATTTA</td>
<td>GTTTCCGGCCAGCAATTA</td>
</tr>
<tr>
<td>Pdgfra</td>
<td>GCTGCCCAACCTGTAAAGAA</td>
<td>GTAAATGGAGCTGACTTGT</td>
</tr>
<tr>
<td>S17</td>
<td>ATGACCTTCCACACAAACGAC</td>
<td>GCCACAGTGATGCTAGTCTGT</td>
</tr>
<tr>
<td>Sox17</td>
<td>GGAATCCACACCGCTCACGT</td>
<td>GGCAAGGAGGAGCAGAAATGT</td>
</tr>
<tr>
<td>Sox7</td>
<td>CAGAGATGAGAGGAAGAGCTGCTG</td>
<td>TCACTCAGATAGGCTGCTCTCTCT</td>
</tr>
<tr>
<td>Sparc</td>
<td>AGGGCCCTGGATCTGGCTAGCTCT</td>
<td>CAAATTCCCTCCCATTCCCAC</td>
</tr>
<tr>
<td>Suv39h1</td>
<td>TGTCACACCTATGCTGGATGCTG</td>
<td>ATTCCTGCTGCTCCATCTTC</td>
</tr>
<tr>
<td>Suv39h2</td>
<td>ATCTACGAATGCAAAGCTCAGGTG</td>
<td>CCCAGCAGAGGCTTAGTCTTCAA</td>
</tr>
<tr>
<td>Tbx3</td>
<td>GAACCTACCTGTTCTCCGGAAAA</td>
<td>CAAATGCCAATGCTGCTGAAAC</td>
</tr>
<tr>
<td>Ywhaz</td>
<td>CGTTGATGGGAGCAGGGATGCTAGTC</td>
<td>TCTGGTGAGGAGCATTTG</td>
</tr>
</tbody>
</table>

* Primers used in Figure2.
Table S5. Sequences of primers used for ChIP-qPCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward (5′ – 3′)</th>
<th>Reverse (5′ – 3′)</th>
<th>Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intergenic</td>
<td>AAGGGGCCCTCGCTTTAAA</td>
<td>AGAGCTCCATGGCAGGTA</td>
<td>Control</td>
</tr>
<tr>
<td>Vstn2l</td>
<td>GCCAGGCTCAGATCTACCTAAG</td>
<td>CAGCAACGACCGTGTCGA</td>
<td>5′ TSS</td>
</tr>
<tr>
<td>Nnat</td>
<td>CTCCTACCCACCCCTCTCTTAC</td>
<td>CCAACGGCGAACCTTTG</td>
<td>Gene body</td>
</tr>
<tr>
<td>Esrrb</td>
<td>CTCACACTCCGCCTTTTC</td>
<td>GGCAGATACGCGAGAAGA</td>
<td>TSS</td>
</tr>
<tr>
<td>Klf4</td>
<td>AGGAGGCGGCTCGCTTTAT</td>
<td>TGTGAGATCCCTGGTGGAAGG</td>
<td>TSS</td>
</tr>
<tr>
<td>Gene body</td>
<td>GCCCTGCCTGTCCTTCTCTA</td>
<td>GGGCTGAGAGACTTGTA</td>
<td>Enhancer</td>
</tr>
<tr>
<td>Fgf5</td>
<td>CTCCAGTGCCATGGGATGTAG</td>
<td>AATCGCTTACGCGGTGTA</td>
<td>Enhancer</td>
</tr>
<tr>
<td>Brachyury</td>
<td>GGCCGACTTTTGTCTCTCC</td>
<td>GGAATGCCTCCTTCTCCTCA</td>
<td>Enhancer 3</td>
</tr>
<tr>
<td>Zic1</td>
<td>CCCAGTCACAGAGAAGAGA</td>
<td>GCCCGGCACTAACAGAATT</td>
<td>Enhancer</td>
</tr>
</tbody>
</table>

Table S6. Sequences of primers used for H3K9me2 ChIP-qPCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward (5′ – 3′)</th>
<th>Reverse (5′ – 3′)</th>
<th>Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brachyury</td>
<td>GGAATCCGCTGTCCTTCT</td>
<td>AGGCTTTCCCTCAGCTAGT</td>
<td>Enhancer</td>
</tr>
<tr>
<td></td>
<td>ACCAGAACCGGCACTGAGGT</td>
<td>GCGTTAATCTCCAGCGAGA</td>
<td>TSS</td>
</tr>
<tr>
<td></td>
<td>CAAGCCTTCCCTGCTGATCT</td>
<td>GGTTACGCCAGCTGACACTCA</td>
<td>Control</td>
</tr>
<tr>
<td>Fgf5</td>
<td>GGGGCGCAGTGGTCTCT</td>
<td>TTGGCTCCTCTCTGAGCT</td>
<td>Enhancer</td>
</tr>
<tr>
<td></td>
<td>GGCTCGGACACATAGCAGTT</td>
<td>GCCCAAGGAAACTTGGACC</td>
<td>TSS</td>
</tr>
<tr>
<td></td>
<td>GTGGCCATGTAATATGACCTGCT</td>
<td>GCACGGCACTGAGATACCA</td>
<td>Control</td>
</tr>
<tr>
<td>Magea2</td>
<td>TTGGTGGACAGGAGAAGCTAGGGA</td>
<td>CGCTCCAGAAGGAAATGGGCAGA</td>
<td>TSS</td>
</tr>
</tbody>
</table>

Supplementary Materials and Methods

Generation and rescue of Jmjd2c-knockout ESCs

Wild-type JM8-ESC lines from the C57BL/6N mouse background and a mutant ESC line carrying one Jmjd2c targeted null allele were obtained from the EUCOMM/IKMC repository (Bradley et al., 2012; Skarnes et al., 2011). The knockout first allele (tm1a) was generated by gene targeting through replacement mutagenesis with a gene-trapping cassette encoding lacZ/β-galactosidase and a neomycin resistance gene, upstream of a “critical exon” common to all predicted Jmjd2c transcripts (Fig. S1A). The generation of biallelic gene targeted cell lines was then carried out through insertional mutagenesis, introducing a second gene-trap cassette through homologous recombination into the second allele (tm2) of Jmjd2c, encoding the hygromycin resistance gene and GFP (Fig. S1A) (C. Fisher and W. C. Skarnes, in...
preparation). Both cassettes are promoterless, hence relying on the active transcription of *Jmjd2c*, and contain an En2 splice acceptor (SA) signal and the SV40 polyadenylation (pA) sequences to ensure transcripts are spliced into the cassette and stopped at the inserted sites, which is predicted to lead to nonsense mediated decay of these transcripts. FRT sites in the first allele allow the removal of the cassette with FLP recombinase, whereas the loxP sites inserted in the vicinity of the critical exon allow the generation of a conditional null allele with Cre recombinase, however neither of these strategies was used in this study. Validation of the correct insertion of the targeting cassettes was achieved by long-range PCR using the Expand Long Template PCR kit (Roche) with the primers listed in Table S2. Two *Jmjd2c*-knockout clones E2 and E3 were selected for further studies, showing a complete loss of Jmjd2c protein expression as assessed by western blotting. The wild-type (WT) and the two *Jmjd2c*-knockout (*Jmjd2c*-KO) embryonic stem cell clones (E2 and E3) derived from the same parental line were routinely cultured in Knockout-DMEM media (Gibco) supplemented with batch tested 10% fetal bovine serum (FBS), β-mercaptoethanol, L-glutamine, penicillin-streptomycin and LIF (made in house). G418 (100 μg/mL) and Hygromycin B (25 μg/mL) were routinely added to the culture medium in the *Jmjd2c*-KO cell lines for selection and removed prior to any experiment.

For rescue of the expression of *Jmjd2c*, the full-length transcript was amplified from the cDNA of WT ESCs and ligated into a pPyCAG-Ires-Puro vector (primer sequences in Table S3). Approximately 3 x 10^5 *Jmjd2c*-KO clone E3 ESCs were transfected with Lipofectamine 2000 (Invitrogen) and 2 μg of pPyCAG-Jmjd2c (Rescue) or an empty pPyCAG vectors (Control), then 1 μg/mL Puromycin (Sigma-Aldrich) was added for selection 24 hours post-transfection. After 8 days of selection individual ESC clones were isolated and expanded.

**Generation of *Jmjd2c*-knockdown ESCs**

Approximately 10^5 E14Tg2A (E14) ESCs were transfected with Lipofectamine 2000 and 1 μg of either of two independent shRNA vectors generated against *Jmjd2c* or a control vector as described in Loh et al., 2007. 24 hours post-transfection 1 μg/mL Puromycin was added for selection and cells harvested after 96 hours of Puromycin selection for subsequent analysis. For generation of stable *Jmjd2c*-knockdown ESC lines, cells were treated 24 hours post-transfection with Puromycin for 8-10 days, colonies picked individually and expanded in GMEM (Gibco) supplemented with 10%
FBS, β-mercaptoethanol, L-glutamine, sodium bicarbonate, sodium pyruvate, non-essential amino acids, penicillin-streptomycin, LIF and Puromycin.

**Generation of FV-Jmjd2c ESCs**

The full-length Jmjd2c transcript was amplified from WT ESCs cDNA and ligated into a pPyCAG-Ires-Puro vector containing a Flag-Flag-V5 at the N-terminal side (primer sequences in Table S3). Approximately 10^6 E14-ESCs were transfected with Lipofectamine 2000 and 4 μg of Flag-Flag-V5-Jmjd2c (FV-Jmjd2c) or an empty vector (Control). 24 hours post-transfection 1 μg/mL Puromycin was added for selection and after 8-10 days of culture individual ESC clones were isolated and expanded indefinitely under selection. Cell lines were maintained in GMEM (Gibco) supplemented with 10% FBS, β-mercaptoethanol, L-glutamine, sodium bicarbonate, sodium pyruvate, non-essential amino acids, penicillin-streptomycin, LIF and Puromycin.

**Self-renewal assay**

To assess the self-renewal ability of ESC populations, 100/cm^2 cells were seeded in duplicate in serum-containing medium supplemented with LIF. After 5 days the colonies were stained for alkaline phosphatase (AP) activity (Sigma-Aldrich) following the manufacturer’s recommendations. Colony morphology was scored as differentiated (<20% stained), mixed (>20%-90% stained), undifferentiated (>90% stained).

**Differentiation of ESCs**

For induction of embryoid bodies (EBs), 10^5/cm^2 cells were cultured in suspension in ultra-low attachment plates (Corning) in ESC media (see Supplemental Materials and Methods) supplemented with 5% FBS without LIF. For all-trans retinoic-acid (atRA) induced differentiation, 2 x 10^5/cm^2 cells were seeded in ESC media for 24 hours. Media was then changed into ESC media supplemented with 5% FBS, and 1 μM of atRA without LIF. EB aggregates and atRA treated cells were collected at the indicated time points for expression analysis, and at day 4 for immunofluorescence staining (atRA assay).

**Conversion of ESCs into XEN cells**

Conversion of ESCs into XEN cells was performed as described in Niakan et al., 2013. Briefly, 3,000/cm^2 cells were plated in ESC media. After 24 hours the media was replaced with XEN derivation media: Advanced RPMI (Gibco) with 15% FBS (Biosera), β-mercaptoethanol and penicillin-streptomycin, freshly supplemented with
10 ng/mL Activin A (R&D), 0.01 μM all-trans retinoic acid (Sigma-Aldrich), 24 ng/mL bFgf (Peprotech) and 1 μg/mL Heparin (Sigma-Aldrich). After 48 hours of derivation cells were re-plated onto a layer of irradiated MEFs, and maintained in media supplemented with bFgf and Heparin for approximately 10 days. Converted XEN (cXEN) colonies were then manually picked and expanded on 0.1% gelatin coated plates in standard XEN media: Advanced RPMI with 15% FBS, β-mercaptoethanol and penicillin-streptomycin. Embryo-derived XENIM8A cells (Kunath et al., 2005) were cultured in the same conditions.

**Conversion of ESCs into EpiSCs**

Conversion of ESCs into EpiSCs was performed as described in Guo et al., 2009. Briefly, ESCs were firstly adapted into serum-free culture conditions in N2B27 (Gibco) medium supplemented with 1 μM PD0325901 (Mek inhibitor), 3 μM CHIR99021 (Gsk3 inhibitor) and LIF (in house) for 7 days prior to conversion (Ying et al., 2008). Approximately 5,000/cm² cells were plated in 2i/LIF media on fibronectin-coated plates. After 24 hours the media was changed into N2B27 supplemented with 20 ng/mL Activin A (in house) and 12 ng/mL bFgf (epiblast media). After 10-12 days converted EpiSC (cEpiSC) colonies were detached following incubation with PBS, and expanded in epiblast media in plates coated with 10% FBS. Embryo derived EpiSCsOct4-GFP (Guo et al., 2009) were cultured in the same conditions.

**Mesoderm induction**

Converted EpiSCs and embryo-derived EpiSCs were cultured in N2B27 (Guo et al., 2009) or chemically defined media with BSA (CDM-BSA) (Brons et al., 2007), respectively, both supplemented 20 ng/mL Activin A (in house) and 12 ng/mL Fibroblast growth factor (bFgf) (Peprotech). Colonies were dissociated by incubation in PBS and seeded in their respective media at a ratio of 1:6 to 1:10 in plates previously coated with 0.1% gelatin followed by MEF medium (Advanced DMEM/F-12 supplemented with 10% FBS). After 24 hours the media was changed into FLYB media consisting of CDM-PVA supplemented with 20 ng/μl bFgf, 10 nM LY294002 (Sigma) and 10 ng/mL BMP4 (R&D). Following 36 hours of mesoderm induction in FLYB conditions, the media was changed into either FB40 – 20 ng/μl bFgf and 40 ng/mL BMP4, or FLYWLDN – 20 ng/ul bFgf, 2 nM LY294002, 2 ng/mL Wnt3a (Peprotech) and 250 nM LDN193189 (Sigma-Aldrich), for lateral plate mesoderm and paraxial mesoderm differentiation, respectively. Differentiated EpiSCs were
harvested at the indicated time points for expression analysis, and at day 4 for flow cytometry analysis and immunofluorescence staining.

**Immunoblotting analysis**

Cell lysis was carried out using RIPA buffer (50 mM Tris, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate and 140 mM NaCl) supplemented with proteinase and phosphatase inhibitors (Roche). Histones were acid extracted as previously described (Shechter et al., 2007). Protein concentrations of whole cell extracts and acid-extracted histones were measured using a Bradford assay (Thermo Fisher Scientific). The appropriate amounts of whole cell lysates (10-50 μg) or histones (2 μg) were resolved on an 8% or 13% SDS-PAGE gel, respectively, and subsequently transferred into methanol-activated polyvinylidene fluoride membranes (GE Healthcare). Membranes were blocked with 5% skimmed milk (Sigma) for 1 hour and incubated with the appropriate antibodies (see Table S1).

**Quantitative PCR**

Total RNA was isolated and DNasel-treated using the RNasey mini kit (Qiagen). Samples were reverse-transcribed using SuperScript II (Invitrogen) following the manufacturer’s instructions. For quantification, cDNA or DNA samples were amplified with Jumpstart SYBR Green PCR Mastermix or KicQstart SYBR Green PCR Mastermix (Sigma), and primer pairs listed in Supplemental Tables S4-S6, using a StepOne™ System (Applied Biosystems). For mesoderm induction RNA extraction was performed with TRIzol (Life Technologies) and samples were reverse transcribed using a QuantiTect Reverse Transcription kit (Qiagen) according to the manufacturer’s directions. cDNA was amplified with a QuantiTect SYBR Green PCR kit (Qiagen) and primer pairs listed in Supplemental Table S4, using a Rotor Gene 6000 PCR system (Corbett Life Science).

**Immunofluorescence staining**

Cells were seeded on gelatinized glass coverslips or 12-well culture plates previously coated with 0.1% gelatin for 10 minutes followed by Advanced DMEM/F-12 with 10% FBS overnight. Cells were fixed in PBS with 4% paraformaldehyde (PFA) for 10 minutes and then permeabilized and blocked at room temperature for 30 minutes using 0.4% Triton X-100 in blocking buffer (10% serum and 90% PBS). Incubation with primary antibody (see Supplemental Table S1) was performed overnight at 4°C, and subsequently incubation with fluorophore-conjugated
secondary antibodies (ThermoFisher) diluted 1:500 for 1 hour at room temperature. Glass coverslips were mounted on Vectashield with DAPI (Vector Laboratories) and visualised using a SP5 Leica laser-scanning confocal microscope or an inverted fluorescent/brightfield microscope.

**Flow cytometry analysis**

Cells were harvested using cell dissociation buffer (Gibco) and $10^4$ cells were blocked in PBS containing 2% FBS, stained for Flk-1 (5 µg/mL anti-Flk-1-Biotin, avas12 a1 clone, eBioscience, followed by 0.4 µg/mL APC-conjugated streptavidin, Biolegend) or Pdgfra (2 µg/mL anti-Pdgfra-PE, clone APA5, eBioscience) and analysed on an Accuri C6 Flow cytometer.

**Co-immunoprecipitation**

Immunoprecipitation of HA-Flag-G9a (HF-G9a) in fractionated nuclear extracts from HeLa cells was performed as previously described in Fritsch et al., 2010. Briefly, HeLa cell lines expressing a HA-Flag-G9a were generated, together with control cell line expressing an empty vector. Cells were lysed in a hypotonic buffer and disrupted with a Dounce homogenizer, and the cytosolic fraction was separated from nuclei (pellet) by centrifugation. The nuclear soluble and chromatin fractions were separated upon incubation in a high salt buffer followed by centrifugation. The chromatin fraction was further digested with micrococcal nuclease (Sigma-Aldrich). G9a-bound complexes were affinity purified by incubation with anti-Flag antibody bound beads (cat# A2220, Sigma-Aldrich). Complexes were eluted with a Flag peptide (Ansynth) and further purified on anti-HA antibody-conjugated agarose beads (cat# A2095, Sigma-Aldrich) and subsequently eluted with the HA peptide (Ansynth). Co-IPs in nuclear extracts of ESCs were performed as previously described (Battisti et al., 2016). Briefly, cells were lysed similarly as above and nuclei pellets were resuspended in sucrose buffer (20 mM Tris pH 7.65, 60 mM NaCl, 15 mM KCl; 0.34 M Sucrose) followed by an incubation in a high salt buffer (20 mM Tris-HCl pH 7.65, 0.2 mM EDTA, 25% glycerol, 900 mM NaCl, 1.5 mM MgCl₂) resulting in a final NaCl concentration of 300 mM. Nuclear extracts were digested with micrococcal nuclease and sonicated for 10 min (15 sec ON, 45 sec OFF) at high frequency. After pre-clearing, immunoprecipitations were performed overnight at 4°C with the corresponding amount of each antibody or IgG control. Complexes were purified with ultralink beads (Perbio), washed in wash buffer (50 mM Tris-HCl, pH 7.65, 150 mM NaCl, Triton X-100 0.5%) and eluted in NuPAGE® LDS Sample Buffer.
(Life Technologies) at 96 °C during 5 min. Immunopurified complexes were resolved on 4-12% SDS-PAGE bis Tris acrylamide gradient gel and immunoblotted with the indicated antibodies (Table S1).

Chromatin immunoprecipitation

In general, chromatin immunoprecipitation (ChIP) of Flag, Jmjd2c, G9a, Med1, Smc1a, Oct4, p300 and H3K27ac followed the procedure described in (Frank et al., 2001), and for H3K9me2 the procedure described in Mozzetta et al., 2014, with the modifications outlined below. Unless stated otherwise, for Jmjd2c, Smc1a, G9a, H3K9me2 ChIPs and Flag-G9a re-ChIPs, cells were fixed with 2 mM Di-Succinimidyl Glutarate (SantaCruz) for 45 minutes at room temperature (Nowak et al., 2005), in addition to an initial 10 minutes fixation step with 1% Formaldehyde (Sigma-Aldrich). Chromatin samples were sonicated on a bioruptor (Diagenode) to produce fragments of 100-500 bp, and ChIPs performed with the antibodies listed in Table S1 and with ProteinG-coupled magnetic Dynabeads (Invitrogen). The amounts of chromatin (DNA or protein) used in each ChIP were as follows: 20 µg of DNA (H3K9me2), 250 µg (G9a), 400 µg (Oct4), 500 µg (Flag, Jmjd2c, p300, H3K27ac) and 800 µg (Med1, Smc1a) of protein. Following washes of bound DNA-protein complexes in the appropriate wash buffers in each referenced protocol, DNA was eluted in 1% SDS at 65°C and treated with 40 ng/µl RNaseA following 0.2 µg/µl Proteinase K. After phenol/chloroform purification, DNA was then precipitated at -20°C with 20-30 µg GlycoBlue carrier (Invitrogen), 1/10 volumes of 3 M NaAc and 2 volumes of 100% ethanol. Resuspended pellets were used for qPCR or for generation of libraries for sequencing. For sequential ChIP (re-ChIP), Flag-bound complexes were eluted at 37 °C for 30 minutes in 75µl of 1% SDS, supplemented with 15mM DTT (Bertero et al., 2015). The eluate was diluted 10 times in the same buffer used for IP and incubated at 4 °C for 5 h, before proceeding to the second round of immunoprecipitations with the G9a antibody, mouse IgG or no antibody (‘beads only’). The ‘beads only’ control was included to normalise for any background from the Flag antibody.

ChIP-sequencing and computational analysis

For sequencing of Flag-Jmjd2c bound DNA fragments, sequencing libraries were prepared using the NEBNext® Ultra™ DNA Library Prep Kit and Multiplex Oligos (New England Biolabs) from 5 ng of DNA. Following analysis on an Agilent Bioanalyzer libraries were pooled and sequenced on an Illumina Genome Analyzer II (Illumina). Quality of the sequenced reads was assessed using the FASTQC
program (Babraham Bioinformatics). Reads were aligned to the UCSC mouse reference genome (mm9) using Bowtie2 (Langmead and Salzberg, 2012), and only uniquely aligned reads were retained. Aligned reads (SAM) were converted into BED format to subsequently generate bigwig files for visualization in the IGV browser (Robinson et al., 2011). For each condition (2i/LIF and serum/LIF), the input and two biological duplicates were sequenced. Due to the high correlation between bigwig files of each pair of replicates, individual BAM files were merged and used in peak calling. List of enriched peaks were obtained using MACS2 with an FDR <0.0001 by calling peaks relative to the respective input control samples (background). Gene annotation to the nearest TSS and motif enrichment analysis was performed using HOMER (Heinz et al., 2010), respectively. For the charts in Figure S8D, the same treatment was applied to the ChIP-seq profiles referenced. Density plots and heatmaps in Figure 3C,E and Figure 5A were generated with deepTools (Ramirez et al., 2014). Overlaps between two genomic intervals were identified with the Intersect function in usegalaxy.org (Blankenberg et al., 2010; Giardine et al., 2005; Goecks et al., 2010). Counts for generation of Venn Diagrams in Figure 5B between three datasets were obtained using the R package ChiPpeakAnno (Zhu et al., 2010). To identify the functional classification listed on Figure 3G, Jmjd2c-bound H3K27-low genomic regions were inputted into GREAT (Genomic Regions Enrichment of Annotations Tool) and tested against the mouse genome (McLean et al., 2010).

For the analysis in Figure 4, S9 and S10 ChIP-seq data were downloaded from Genome Expression Omnibus (GEO) as SRA files, converted to FASTQ format using fastq-dump.2.4.2, evaluated using FASTQC program (Babraham Bioinformatics), trimmed and filtered using Trimmomatic-0.33 (LEADING:10 TRAILING:10 SLIDINGWINDOW:4:18 MINLEN:20) (Bolger et al., 2014). Sequences were aligned to the mm9 version of the mouse genome using Bowtie2. To calculate the average ChIP-seq read coverage at Jmjd2c-bound sites, BAM files were read into R, duplicate reads were removed and the bam files were converted to coverage objects using the Genomic Alignments package (Lawrence et al., 2013). The coverage objects were normalised to both sequencing depth and their respective inputs as follows:

\[
F = \frac{10^6}{T} \\
N_s = CF \\
N = \frac{N_s}{T}
\]
Where \( T \) is the total number of reads, \( F \) is the sequencing depth normalisation factor, \( C \) is the pre-normalised read coverage, \( N_s \) is the sequencing depth normalised read coverage, \( I \) is the input read coverage and \( N \) is the sequence read and input normalised read coverage.

Coverage heatmaps were generated using the gplots package (Zhang, 2016). To plot the coverage heatmaps values greater than 3 standard deviations from the mean were removed and replaced values imputed by the mice R package. The largest number of values replaced from a single dataset was 69 out of 10,000 (0.7%). Pearson correlation coefficients of the average read coverage were calculated and visualised as heatmaps.

The accession numbers of the published ChIP-seq datasets analysed are listed below. Raw or treated files were obtained directly from the GEO repository, the mouse ESC ChIP-seq compendium (Martello et al., 2012) or the Supplementary Information of the referenced paper. For G9a, bigwig files were generated using the parameters described in Mozzetta et al., 2014.

<table>
<thead>
<tr>
<th>Accession</th>
<th>Reference</th>
<th>Factor</th>
<th>BED files</th>
<th>BigWig files</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSE11724</td>
<td>Marson et al., 2008</td>
<td>Oct4</td>
<td>Kagey et al., 2010</td>
<td>Compendium</td>
</tr>
<tr>
<td>GSE22562</td>
<td>Kagey et al., 2010</td>
<td>Med1</td>
<td>Kagey et al., 2010</td>
<td>Compendium</td>
</tr>
<tr>
<td>GSE22562</td>
<td>Kagey et al., 2010</td>
<td>Smc1a</td>
<td>Kagey et al., 2010</td>
<td>Compendium</td>
</tr>
<tr>
<td>GSE24165</td>
<td>Creyghton et al., 2010</td>
<td>p300</td>
<td>Creyghton et al., 2010</td>
<td>Compendium</td>
</tr>
<tr>
<td>GSE46536</td>
<td>Mozzetta et al., 2014</td>
<td>G9a</td>
<td>GEO</td>
<td>Generated</td>
</tr>
<tr>
<td>GSE43229</td>
<td>Das et al., 2014</td>
<td>Jmjd2c</td>
<td>Generated</td>
<td>Generated</td>
</tr>
<tr>
<td>GSE53936</td>
<td>Pedersen et al., 2014</td>
<td>Jmjd2c</td>
<td>Generated</td>
<td>Generated</td>
</tr>
<tr>
<td>GSE48519</td>
<td>Hon et al., 2014</td>
<td>H3K4me1</td>
<td>-</td>
<td>GEO</td>
</tr>
<tr>
<td>GSE48519</td>
<td>Hon et al., 2014</td>
<td>H3K27ac</td>
<td>-</td>
<td>GEO</td>
</tr>
<tr>
<td>GSE48519</td>
<td>Hon et al., 2014</td>
<td>H3K4me3</td>
<td>-</td>
<td>GEO</td>
</tr>
<tr>
<td>GSE27827</td>
<td>Lienert et al., 2010</td>
<td>H3K4me2</td>
<td>-</td>
<td>GEO</td>
</tr>
<tr>
<td>GSE54412</td>
<td>Liu et al., 2015</td>
<td>H3K9me2</td>
<td>-</td>
<td>Generated</td>
</tr>
<tr>
<td>GSE43229</td>
<td>Das et al., 2014</td>
<td>H3K9me2</td>
<td>-</td>
<td>Generated</td>
</tr>
</tbody>
</table>

**RNA-seq analysis**

RNA-seq was treated as described above and were aligned to the mm9 version of the mouse genome using tophat-2.1.0 (Trapnell et al., 2009). Transcript assembly and differential expression analysis was performed using the cufflinks-2.2.1 suite of
software (Trapnell et al., 2013; Trapnell et al., 2010). TopHat aligned reads were assembled using Cufflinks, the final transcriptome assembly was generated using Cuffmerge and differential expression was evaluated using Cuffdiff. Chi-square tests were performed on the Cuffdiff evaluated differentially expressed gene lists. The genes were divided into Jmjd2c-G9a regulated and all other annotated genes. Up and downregulated genes were defined as those with statistically significant (q-value <0.05) log2 fold-changes in expression between the G9a-knockout and wild-type cells. Non-differentially expressed genes were defined as those with a non-significant change in expression (q-value >0.05). The functional classification of both sets of genes was identified through a statistical enrichment test using default settings in PantherDB GO (Mi et al., 2013).

**Capture Hi-C in ESCs**
To identify integration profile for promoter of Foxa2 in Figure S13, the CHiCAGO pipeline was used to output scores for capture Hi-C data from the study Joshi et al., 2015. A manuscript on the CHiCAGO pipeline (Cairns et al., 2016) is publically available, with the pipeline itself at regulatorygenomicsgroup.org/chicago. Probe targeted Dpn2 fragments from Foxa2 gene promoter were used as regions of interest and interactions anchored at the same region, with a threshold CHiCAGO score of 5 were considered. For further information on capture Hi-C or interaction calling and scoring please refer to (Joshi et al., 2015) and (Cairns et al., 2016).

**Supplementary References**


